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 C h a p t e r  1  
GENERAL INTRODUCTION 
Schizophrenia  
Schizophrenia is a severe mental disorder that is marked by distortions of reality, disturbances in 
perception, intellectual functioning, motivation and motor behaviour. Statistical analyses of 
schizophrenic patients and their symptoms led to the identification of three groups of symptoms 
(Liddle, 1987; Arndt, Alliger et al., 1991; Bilder, Mukherjee et al., 1985; Kulhara, Kota et al., 1986; 
Malla, Norman et al., 1993). 
The first group of these symptoms is called reality distortion. It consists of delusions and 
hallucinations. Although all kind of hallucinations can occur in schizophrenic patients auditory 
hallucinations are most common. Persecutory delusions or delusions of reference are also quite 
common. However, bizarre and not understandable delusions are most characteristic for 
schizophrenia since the other delusions are also found in other psychotic diseases. The second 
group of symptoms is disorganization, characterised by incoherent or irrelevant speech, 
inappropriate affect and behaviour. The third group finally is the psychomotor poverty syndrome. 
These symptoms are associated with slowing down of (mental) activity and consist of symptoms 
like blunted affect, poverty of speech, decreased spontaneous movement and planning difficulties. 
Recent psychopathological research has provided strong evidence that these three different groups 
of symptoms are associated with different brain activity patterns (Liddle, 2000). Reality distortion is 
accompanied by an increased blood flow in the medial temporal cortex and a decreased blood flow 
in the posterior cingulated cortex. Disorganization is associated with an increased blood flow in the 
right anterior cingulated cortex and a decreased blood flow in the right ventral frontal cortex. The 
psychomotor poverty syndrome, finally, is accompanied by increased blood the caudate nucleus 
and decreased blood flow in the left frontal and parietal cortex. 
As an alternative, the symptoms of schizophrenia can also be classified as positive and negative 
symptoms. Negative symptoms are symptoms that reflect a decrease or absence of a process that is 
present in normal individuals, like poverty of speech, flat affect and decreased amount of voluntary 
activity. These symptoms perfectly correspond to the symptoms of psychomotor poverty. Positive 
symptoms are those that reflect the presence of a process that is not present in normal individuals, 
like delusions, hallucinations, formal thought disorder, bizarre behaviour and inappropriate affect.  
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The aetiology of schizophrenia is still unclear however; the involvement of factors like genetics and 
stress has been mentioned in this respect. These factors will be discussed in detail in the following 
sections.   
Genetics in Schizophrenia  
The study from Gottesman and Shields (Gottesman and Shields, 1982) has shown an increased risk 
of developing schizophrenia in affected families. The risk of developing this illness in the general 
population is about 1% whereas the risk of siblings and offspring of schizophrenics is in the range 
of 10% and it is even increased up to 46% in children with two schizophrenic parents. However 
one should be aware that relatives of schizophrenics not only share parts of their genes but also 
their social environment. Against the background of the influence of psychosocial factors and stress 
on schizophrenia (see below) this should not be overlooked. This problem was attacked by 
comparing the vulnerability risk of monozygotic and dizygotic twins. Usually both groups of twins 
share equal part of their social environment but monozygotic twins share 100% of their genes 
whereas dizygotic twins only share 50% of their genes. Thus if schizophrenia is genetically based, 
the risk must be higher in monozygotic twins then in dizygotic twins. In fact monozygotic twins 
have a risk of about 57% to become schizophrenic compared to dizygotic twins which have a risk 
of about 12 % (Faraone and Tsuang, 1985). However the statement that monozygotic twins and 
dizygotic twin share equal part of their environment has been criticised because monozygotic twins 
are often dressed alike or share more similar interests then dizygotic twins. Basically it has been 
argued that the “microenvironment” between monozygotic and dizygotic twins differs and this may 
account for the increased concordance rate in monozygotic twins. Gottesman and colleague 
(Gottesman and Shields, 1982) have investigated the concordance rate in monozygotic twins that 
were reared separately and found a concordance rate of 58% which is similar to that of 
monozygotic twins reared together. Based on these results, the authors have concluded that the 
shared microenvironment contributes little to the development of schizophrenia. Further evidence 
about the influence of genes on schizophrenia comes from adoption studies. The study by Heston 
(Heston, 1966) for example has compared a group of adopted children whose biological mothers 
were schizophrenic with a control group of adopted children whose biological mothers were not 
schizophrenic. None of the children in the control group became schizophrenic whereas 11% of 
the children in the group with schizophrenic biological mother developed this disease.  
Thus the evidence that the genetic background contributes to this illness is quite clear. However if 
schizophrenia were only genetically based one would expect to find concordance rates around 
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100% in monozygotic twins which is not the case. Thus other non-genetic factors must also 
contribute to the development of this disease. In these respect environmental factors, and in 
particular stress have been proposed.  
Stress in Schizophrenia  
Stress appears to play a dual role in schizophrenia. First, exposure to stress early in life has been 
proposed to contribute to the development of the disease itself probably by disturbing the normal 
brain development. The second effect of stress becomes apparent when the disease is manifest. In 
schizophrenic patients stress has been found to increase the risk of relapse or, in other words, to 
trigger the occurrence of a psychotic episode.  
Perinatal stressful experiences like early parental loss (Agid, Shapira et al., 1999) or growing up in an 
urban region compared to a rural region increase the risk to develop schizophrenia (David, Lewis et 
al., 1992; Takei, O´Callaghan et al., 1992). Also obstetric complications during delivery (Owen, 
Lewis et al., 1988) have been found to increase the risk for developing this disease. In addition, 
other early experiences in life, like prenatal exposure to influenza (Mednick, Machon et al., 1988; 
O´Callaghan, Sham et al., 1991; Takei, Mortensen et al., 1996) or maternal malnutrition (Susser and 
Lin, 1992) have been found to be involved in the development of schizophrenia.  
These findings have led to the so-called neurodevelopmental hypothesis of schizophrenia, which 
states that early life events affect the normal development resulting in abnormal brain and body 
morphology and ultimately in schizophrenia. In fact several abnormalities in the brain of 
schizophrenic patients have been found, like enlarged ventricles, reduced volume of the basal 
ganglia, temporal lobe and the limbic region, many of which appear to be present at the onset of 
the disease and do not change much during the course of the illness (Raz and Raz, 1990). Studies 
about the cytoarchitecture of the brain are of special interest since it is largely determined during 
foetal brain development. In 1986 Jacob and Beckman (Jakob and Beckmann, 1986) reported 
abnormalities in the superficial layers of the rostral entorhinal cortex in schizophrenic patients. 
They found that certain neurons (the so called pre-alpha neurons) are ordered atypically instead of 
being ordered in clusters. Furthermore they found a reduction in neuron number and a poorer 
development. Since the laminar pattern in the entorhinal cortex is set in the second trimester of 
gestation, the authors have concluded that an abnormal neuronal migration in schizophrenics 
occurs during this prenatal period. This finding was recently confirmed by Arnold et al (Arnold, 
Han et al., 2000). Furthermore even though the position of the pre-alpha cells in the layer II of the 
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entorhinal cortex is not equally distributed (in the anterior compartment the position is deeper 
relative to the pinal surface), the pre-alpha cells are nevertheless located deeper and at different 
places in the entorhinal cortex in schizophrenics compared to controls (Falkai, Schneider-Axmann 
et al., 2000). Thus there are clear indications that schizophrenic patients display impairments in the 
normal brain development. 
As soon as schizophrenia has become manifest, usually after puberty, abrupt changes in life or 
stressful experiences have been found to increase the risk of relapse (Brown and Birley, 1968; 
Bebbington, Wilkins et al., 1993; Jones, Bebbington et al., 1993). In addition, the expression of 
criticism and hostility towards a schizophrenic patient by relatives has been found to increase the 
risk of relapsing. If the family behaves supportive and positive, the risk of a breakdown is much 
lower (Brown, Birley et al., 1972; Vaughn and Leff, 1976). These findings have led to the concept 
that “Expressed Emotion” (EE) increases the risk of relapse. Based on a standard interview with 
relatives of the patient, dealing with the illness, the families can be divided in high EE or low EE 
families. Based on this concept several studies have confirmed the finding of Brown and colleagues 
for an increased risk of relapse in a high EE-family (for review see : Koenigsberg and Handley, 
1986; Butzlaff and Hooley, 1998). Based on these studies one can conclude that stress is worsening 
the symptoms of schizophrenia.  
The effects of stress on the body are among others regulated by the so-called hypothalamo-
pituitary-adrenal (HPA) axis. Basically, stress induces the release of corticotropine releasing 
hormone (CRH) from the paraventricular nuclei of the hypothalamus (PVN) which induces the 
release of the adrenocorticotropine hormone (ACTH) and arginine vasopressine in the pituitary. 
Finally ACTH induces the release of cortisol (and corticosteroids in animals) from the adrenal 
cortex.  
It should be noted that alterations in this system have been found in schizophrenic patients for 
example hypercortisolemia (Gil-Ad, Dickerman et al., 1986; Whalley, Christie et al., 1989; Breier 
and Buchanan, 1992). In addition, negative symptoms have been found to correlate with the plasma 
levels of ACTH and cortisol (Shirayama, Hashimoto et al., 2002). Furthermore a stress induced 
activation of the HPA-axis induces higher levels of ACTH and cortisol in the plasma of 
schizophrenic patients than in control subjects (Elman, Adler et al., 1998). Finally, after suppression 
of the HPA-axis with dexamethasone, CRH induces the release of higher levels of cortisol in 
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schizophrenic patients compared to controls (Lammers, Garcia-Borreguero et al., 1995). Thus the 
system itself that is affected by stress is also affected in schizophrenia. 
Stress also activates the dopaminergic system. For example, tail shocks increase dopamine release in 
the nucleus accumbens and the frontal cortex in rats (Abercrombie, Keefe et al., 1989; Klitenick, 
Taber et al., 1996). Likewise, even very mild stressors, such as novelty or handling can induce the 
release of dopamine from the nucleus accumbens and the prefrontal cortex (Feenstra, Botterblom 
et al., 1995; Saigusa, Tuinstra et al., 1999). Moreover, repeated stress has been found to alter brain 
dopamine receptors (Puglisi-Allegra, Kempf et al., 1991). 
It is well known that amphetamine and other dopamine releasing drugs can induce a state 
resembling paranoid schizophrenia in normal individuals (Connell, 1958; Griffiths, Cavanaugh et 
al., 1972; Angrist, Sathanathan et al., 1974). Furthermore, increased levels of dopamine (Bird, 
Spokes et al., 1977) and increased numbers of D2 receptors have been found in the nucleus 
accumbens, basal ganglia and substantia nigra in post-mortem brains of schizophrenics (Owen, 
Cross et al., 1978; Mackay, Iversen et al., 1982; Seeman, Ulpian et al., 1984). In addition, it has been 
recently shown that amphetamine induces a much stronger dopamine release in schizophrenic 
patients than in controls (Abi-Dargham, Gil et al., 1998) indicating not only differences in 
dopamine receptor levels but also functional differences in the dopamine release of the patients. In 
other words there is clear evidence that the dopaminergic system in schizophrenic patients is 
impaired. Thus the dopaminergic system that is affected by stress is also itself affected in 
schizophrenia.  
The third important system involved in the regulation of the stress response is the noradrenergic 
system (Chrousos, 1988). Stress activates the sympathetic nervous system, which releases 
noradrenaline from the adrenal medulla into the blood stream. In addition, stress activates central 
noradrenergic cells, such as the locus coeruleus and the nucleus of the tractus solitarius (Cullinan, 
Herman et al., 1995; Dent, Smith et al., 2001; Saavedra and Torda, 1980; Teppema, Veening et al., 
1997). This is also reflected in an increased release of noradrenaline in the nucleus accumbens, 
prefrontal cortex and hippocampus (Feenstra, Botterblom, and Mastenbroek, 2000; Ihalainen, 
Riekkinen et al., 1999). 
There is clear evidence that also the noradrenergic system is impaired in schizophrenic patients. For 
example, abnormal levels of noradrenaline and its metabolites have been found in post-mortem 
brains (Farley, Price et al., 1978; Bird, Spokes et al., 1979; Crow, Baker et al., 1979). In addition 
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elevated levels of noradrenaline and it metabolites have been found in cerebrospinal fluid (csf) of 
schizophrenics (van Kammen, Peters et al., 1989; Gomes, Shanley et al., 1980; Lake, Sternberg et 
al., 1980; Kemali, Del Vecchio et al., 1982; Hornykiewicz, 1986; van Kammen and Antelman, 
1984). Even more important the symptoms of paranoid schizophrenia correlate with cerebrospinal 
fluid noradrenaline levels (van Kammen and Gelernter, 1987). Likewise, Dajas and colleagues have 
found a correlation between plasma noradrenaline, positive symptoms, overall psychopathology 
and paranoid symptoms (Dajas, Barbeito et al., 1983). Thus the noradrenergic system that is 
affected by stress is also itself affected in schizophrenia.  
Interestingly, noradrenaline is known to control both the HPA-axis as well as the dopaminergic 
system. For example noradrenaline has been found to alter the dopamine activity at the level of the 
substantia nigra (Donaldson, Dolphin et al., 1976). Furthermore, there are several indications about 
an interaction between noradrenaline and dopamine in the prefrontal cortex (for review see: Tassin, 
1992). For example, stimulation of prefrontal alpha-adrenoceptors has been found to inhibit the 
dopamine activity at the level of the D1 receptors in the prefrontal cortex (Tassin, Studler et al., 
1986). Furthermore, recent microdialysis study by Kawahara and colleagues have shown that local 
activation of the locus coeruleus increases both noradrenaline and dopamine in the prefrontal 
cortex (Kawahara, Kawahara et al., 2001). However noradrenaline also controls dopamine in other 
brain nuclei. For example local activation of accumbal beta2 adrenoceptors in rats has been found 
to increase dopamine overflow in nucleus accumbens slices (Nurse, Russell et al., 1985). A recent 
microdialysis study showed that not only beta2-adrenoceptor agonists but also alpha1-adrenoceptor 
agents influence mesolimbic dopamine release (Tuinstra and Cools, 2000). 
Noradrenaline also interferes with the HPA-axis. Several studies have shown that noradrenaline 
stimulate the HPA-axis through activation of CRH-release (for review see:  Plotsky, Cunningham et 
al., 1989). Thus, intracerebroventricular injections of noradrenaline elicits a dose dependent release 
of CRH an effect that is blocked by an alpha1-antagonist (Plotsky, 1987). CRH is synthesised mainly 
in the parvocellular division of the PVN (Liposits, Phelix et al., 1987), a structure that is innervated 
by  noradrenergic neurons arising in the locus coeruleus (Sawchenko and Swanson, 1982).  
The fact that the dopaminergic system and the HPA-axis are impaired in schizophrenics together 
with the fact that noradrenaline appears to control both systems suggests a central role of 
noradrenaline in schizophrenia. This is in line with the elevated levels of noradrenaline found in 
these patients. Furthermore the functional connection between the locus coeruleus and the PVN 
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on the one hand, and between the locus coeruleus and the dopaminergic cells on the other hand 
further suggest a central role of noradrenaline in the symptoms of schizophrenia. Therefore, in the 
present thesis, we focus on the role of stress and noradrenaline in schizophrenia. In order to 
investigate this, we used the so called apomorphine-susceptible (APO-SUS) and apomorphine 
unsusceptible (APO-UNSUS) rats because these rats have several features that make them a perfect 
model for these investigations as discussed below.   
Apomorphine-Susceptible and Apomorphine-unsusceptible rats 
APO-SUS and APO-UNSUS rats were originally developed in our laboratory on the basis of their 
response to apomorphine (Cools, Brachten et al., 1990). Whereas APO-SUS rats show an intense 
gnawing response to apomorphine, APO-UNSUS rats show only a very weak gnawing response to 
this drug. From approximately 1985 these rats have been pharmacogenetically bred using a 
procedure to minimize inbreeding. In 1995 a replication breeding line was started with an identical 
procedure (Ellenbroek, Sluyter et al., 2000). 
Like in schizophrenics, the APO-SUS rats display impairments in their stress response, in their 
noradrenergic and dopaminergic system as well as in their HPA-axis. For example APO-SUS rats 
show a much stronger locomotor response to novelty stress than APO-UNSUS rats (Cools, 
Brachten, Heeren, Willemen, and Ellenbroek, 1990).  
With respect to the noradrenergic system, pharmaco-behavioural studies have indicated that APO-
UNSUS rats have a high functional noradrenergic activity in the ventral striatum at rest, whereas 
the APO-SUS have a low functional noradrenergic activity in the ventral striatum at rest. 
Furthermore there is evidence that stress increases the functional noradrenergic activity in APO-
SUS rats but decreases the functional noradrenergic activity in APO-UNSUS rats (Cools, Brachten, 
Heeren, Willemen, and Ellenbroek, 1990). In addition, APO-SUS rats show a stronger locomotor 
response than APO-UNSUS rats after application of the alpha1 adrenoceptor agonist 
phenylephrine into the nucleus accumbens (Ellenbroek and Cools, 1993). 
Given the differential sensitivity of APO-SUS and APO-UNSUS rats to the dopaminergic agonist 
apomorphine, it is not surprising that these animals also show other differences in their 
dopaminergic system. Thus an increase in mRNA for tyrosine hydroxylase in APO-SUS rats has 
been reported (Rots, Cools et al., 1996). Furthermore binding studies have indicated that APO-SUS 
rats have increased number of D2 receptors in the projection area of the substantia nigra (Rots, 
Cools, Berod, Voorn, Rostene, and deKloet, 1996).  
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As far as the HPA-axis is concerned, plasma levels of ACTH and CRH-mRNA in the 
paraventricular nucleus are elevated in APO-SUS rats under baseline conditions. Furthermore mild 
stress induces a stronger and longer lasting increase of ACTH in APO-SUS rats compared to APO-
UNSUS rats (Rots, Cools et al., 1995).  
Given the alterations in stress sensitivity and in the noradrenergic, dopaminergic and HPA-axis 
systems, it is not surprising that the APO-SUS rats show a number of abnormalities that resemble 
schizophrenia (for a recent review see: Ellenbroek and Cools, 2002). Apart from the above 
mentioned ones, APO-SUS rats display abnormalities in the immune system (i.e. a TH2 dominance) 
that has also been observed in schizophrenic patients. Recently we also could show that APO-SUS 
rats are more resistant to cancer metastasis, similar to schizophrenic patients (Teunis, Kavelaars et 
al., 2002). Finally APO-SUS rats show an abnormal prepulse inhibition and latent inhibition 
(Ellenbroek, Geyer et al., 1995). Especially the reduced prepulse inhibition is of interest, as it has 
been repeatedly proposed to represent an interesting animal model for specific aspects of 
schizophrenia (Ellenbroek and Cools, 2000; Ellenbroek and Cools, 2002). For this reason, we 
decided to use this paradigm in our experiment. 
The prepulse inhibition 
A contraction of skeleton and facial muscles as a response to a sudden stimulus is known as the 
startle reflex. Whereas in humans the eyeblink component of the startle is measured, the whole 
body flinch is measured in rats or mice. In either case similar stimuli are used. The primary startle 
circuit consists of the auditory nerve, the cochlear root neurons, the nucleus reticularis pontis 
caudalis (PnC) and the spinal motor neurons (Koch, 1999). The startle response displays several 
forms of plasticity like habituation, fear potentation and prepulse inhibition. Prepulse inhibition is a 
reduction of the startle response to a stimulus (the so-called pulse) induced by a relative weak 
preceding stimulus (the so-called prepulse). It should be noted that the prepulse itself is too weak to 
induce a startle response in the subject. In order to inhibit the startle response the prepulse must 
precede the pulse by 30-500 ms in both humans and rats. The prepulse inhibition is not a form of 
learning or conditioning, since it occurs on the first exposure to the combination of pulse and 
prepulse and, furthermore, it shows no sign of habituation or extinction after multiple trials. 
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  Fig 1 The prepulse inhibition circuit 
The neuronal elements that contribute to prepulse inhibition can be divided in those that modulate 
prepulse inhibition versus those that regulate prepulse inhibition. The elements that regulate 
prepulse inhibition are activated by the prepulse itself and transmit the neuronal and behavioural 
consequences of the prepulse; namely a reduction in startle response. Basically this circuit consists 
out of the auditory nerve, the cochlear nuclei, the colliculus inferior, the colliculus superior and the 
pedunculoponine tegmental nucleus. This circuit impinges on the pontis caudalis (PnC) as part of 
the primary startle circuit. Modulation of the prepulse inhibition is carried out by neuronal 
connections between limbic cortex, the nucleus accumbens, and the ventral palidum (Swerdlow, 
Caine et al., 1992; Koch and Schnitzler, 1997; Swerdlow and Geyer, 1998; Swerdlow and Geyer, 
1999). At the level of the PnC this modulating circuit interacts with the primary startle circuit 
(Fendt, Li et al., 2001). This circuit modulates the prepulse inhibition by altering the impact of the 
prepulse on the startle response (see: Fig 1). 
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Reductions in  prepulse inhibition have been found in schizophrenic patients (Braff, Stone et al., 
1978; Braff, Grillon et al., 1992; Braff, Geyer et al., 2001) and even drug naïve schizophrenics 
(Weike, Bauer et al., 2000; Mackeprang, Kristiansen et al., 2002). These deficits in prepulse 
inhibition correlate with various symptoms in patients (Braff, Swerdlow et al., 1999). However it 
should be noted that disturbances in prepulse inhibition are not exclusive for schizophrenia since 
these disturbances are also present in other neuropsychiatric diseases like obsessive compulsive 
disorder (Braff, Geyer, and Swerdlow, 2001) Huntington’s disease (Swerdlow, Paulsen et al., 1995), 
attention deficit disorder (Ornitz, Hanna et al., 1992) Tourette's syndrome (Castellanos, Fine et al., 
1996) and posttraumatic stress disorder (Grillon, Morgan et al., 1996). 
Given the fact that dopamine plays a dominant role in schizophrenia it is important to realise that 
the prepulse inhibition is closely related to the dopamine function. Thus Hutchinson and Swift 
have demonstrated that d-amphetamine reduces prepulse inhibition in normal human subjects 
(Hutchison and Swift, 1999). In addition the D2 agonist bromocriptine reduces the prepulse 
inhibition significantly in healthy subjects an effect that is antagonised by the D2 antagonist 
haloperidol (Abduljawad, Langley et al., 1999). It is less clear whether antipsychotics can also 
reverse the deficit observed in schizophrenic patients. In  the only longitudinal study reported so 
far, no effects of risperidone or zuclopenthixol on the prepulse inhibition deficit have been 
observed in drug naïve patients, in spite of a clear therapeutic effect of both drugs (Mackeprang, 
Kristiansen, and Glenthoj, 2002). Based on this study it appears that the disturbance in prepulse 
inhibition in schizophrenic patients is a phenomenon that is independent from the treatment with 
antipsychotic drugs, although the effects of other antipsychotic drugs have not been studied in any 
detail yet.  
The role of dopamine in prepulse inhibition has been investigated in detail in rodents (for extensive 
review see: Geyer, Krebs-Thomson et al., 2001). Thus Mansbach and colleagues (Mansbach, Geyer 
et al., 1988) have shown that the dopamine agonist apomorphine disrupts prepulse inhibition in 
naïve rats and that this effect is blocked by haloperidol. On the other hand, the selective D1 agonist 
SKF38393 does not disturb prepulse inhibition (Peng, Mansbach et al., 1990; Wan, Caine et al., 
1996; Zhang, Bast et al., 2000). However, one study has reported a reduction in prepulse inhibition 
after application of the D1-agonist SKF82958 (Wan, Caine, and Swerdlow, 1996). This might have 
been due to a relative weak selectivity to D1-receptors of this drug over D2-receptors. So far there is 
little evidence that the D3 or D4 receptors are involved in modulating prepulse inhibition since in 
knockout-mice the disruptive effect of amphetamine on prepulse inhibition is attenuated only in 
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mice lacking the D2 receptors but not in D3 or D4 knockouts (Ralph, Varty et al., 1999). 
Furthermore, there are clear indications that especially the D2 receptors in the nucleus accumbens 
are involved in the dopamine effect on prepulse inhibition (Swerdlow, Braff et al., 1990). Thus at 
present these data suggest that the disruptive effects of dopamine agonists on prepulse inhibition 
are based on their activity at the level of the D2 receptors most likely located in the nucleus 
accumbens.  
Despite the fact that noradrenaline plays a role in schizophrenia and has a modulatory influence on 
dopamine, only a few studies have investigated the role of noradrenaline in prepulse inhibition. 
Basically it has been found that the alpha2 agonist clonidine and alpha2 antagonist RX821002 have 
no effect on prepulse inhibition (Kehne, Padich et al., 1996; Bakshi and Geyer, 1997). However the 
alpha1 agonist cirazoline reduces the prepulse inhibition (Carasso, Bakshi et al., 1998; Varty, Bakshi 
et al., 1999) and at least one study has shown that the alpha1-antagonist prazosin increases the 
prepulse inhibition in rats (Depoortere, Perrault et al., 1997).  
At present the noradrenergic agents have been given systemically, thus it is not known which brain 
structures are involved in the modulatory effect of noradrenaline on prepulse inhibition. However 
the fact that noradrenaline can increase the dopamine release in the nucleus accumbens (Tuinstra 
and Cools, 2000) together with the fact that an increase in dopamine activity in this nucleus can 
reduce prepulse inhibition (Swerdlow, Geyer et al., 2001) suggests that this nucleus which contains 
both beta and alpha-adrenoceptors (Nurse, Russell, and Taljaard, 1985) plays a central role. The 
noradrenergic input to the nucleus accumbens is provided by the locus coeruleus (Speciale, Crowley 
et al., 1978) and the medullary group (Delfs, Zhu et al., 1998; Lindvall and Bjorklund, 1983; 
Rainbow, Parsons et al., 1984; Sawaya, Dolphin et al., 1977). Based on these notions it seems likely 
that noradrenaline modulates prepulse inhibition by controlling the dopamine release in the nucleus 
accumbens. Since the noradrenergic input of the nucleus accumbens is provided by the locus 
coeruleus and the medullary group, it is likely that also these nuclei play a role in modulating 
prepulse inhibition.  
Aim and outline of the thesis 
Thus an impaired stress response and altered noradrenaline levels appear to be crucial in 
schizophrenia. However, the exact role of noradrenaline, and the brain mechanisms involved in this 
are far from clear. The aim of this study is therefore to investigate the role of stress and 
noradrenaline in relation to schizophrenic symptoms. Because of their known similarities with 
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schizophrenic patients we used the APO-SUS rats, and since disturbances in prepulse inhibition 
have been found in schizophrenics as well as in APO-SUS rats we used this paradigm as the read-
out parameter.  
Since stress worsens the symptoms of schizophrenia, we first investigated whether stress also 
disrupts prepulse inhibition by subjecting rats to a short term social stress, namely one day of 
isolation. These experiments are described in chapter 2. It was found that only stressed APO-SUS 
rats show a reduction in prepulse inhibition, whereas stressed APO-UNSUS rats even show an 
increase in prepulse inhibition. We know that stress increases the functional noradrenergic activity 
in APO-SUS rats but decreases it in APO-UNSUS rats. This links stress with the noradrenergic 
activity of these rats and suggest that an increased noradrenergic activity reduces prepulse 
inhibition. This is in line with the elevated levels of noradrenaline and the reductions of prepulse 
inhibition that has been found in schizophrenic patients. In order to investigate whether an increase 
in noradrenergic activity indeed reduces prepulse inhibition, we tested the effect of the alpha1-
adrenoceptor agonist cirazoline and the beta2-agonist clenbuterol in non-stressed APO-SUS and 
APO-UNSUS rats (chapter 3).We were able to demonstrate that cirazoline reduces prepulse 
inhibition in non-stressed APO-SUS rats, giving clear evidence that the noradrenergic activity 
modulates the prepulse inhibition in these rats. However it is not known which brain nuclei are 
involved in this process. As mentioned in the Introduction the noradrenergic terminals of the locus 
coeruleus innervates the PVN known to release CRH. Furthermore, this nucleus projects to the 
nucleus accumbens, a structure that is well known to modulate prepulse inhibition. This strongly 
suggests that the locus coeruleus plays a role in modulating prepulse inhibition. In order to 
investigate the role of this nucleus in prepulse inhibition we destroyed the terminals of the locus 
coeruleus with the help of the neurotoxin DSP4 (chapter 4). These experiments were carried out 
in stressed and non-stressed APO-SUS and APO-UNSUS rats. It was found that the prepulse 
inhibition is reduced in stressed APO-SUS and increased in stressed APO-UNSUS rats. No effect 
was found in non-stressed rats. These data confirm that the locus coeruleus is indeed involved in 
modulating prepulse inhibition. As mentioned above the locus coeruleus projects to the nucleus 
accumbens and several studies have shown that the dopamine activity within this nucleus 
modulates prepulse inhibition. Interestingly noradrenaline is known to control the dopamine release 
in this nucleus. These findings suggest that the noradrenergic activity in the nucleus accumbens 
modulates prepulse inhibition. Therefore we investigated the effect of accumbal injected 
noradrenergic drugs on prepulse inhibition in chapter 5. We tested the alpha1-adrenoceptor agonist 
phenylephrine, the alpha1-adrenoceptor antagonist phentolamine and the beta2-adrenoceptor 
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agonist isoproterenol and found that the noradrenergic activity in the nucleus accumbens 
modulates prepulse inhibition. Notably both types of accumbal adrenoceptors are involved in 
modulating prepulse inhibition. In chapter 6 gives a summary of the main results. Finally in 
chapter 7 we will discuss the consequences of the present findings for the neuronal regulation of 
the prepulse inhibition and the impact of theses findings for the treatment of schizophrenia.  
Reference List 
1. Abduljawad KA, Langley RW, Bradshaw CM, Szabadi E (1999) Effects of bromocriptine and haloperidol on 
prepulse inhibition: comparison of the acoustic startle eyeblink response and the N1/ P2 auditory-evoked 
response in man. J.Psychopharmacol. 13: 3-9 
2.  Abercrombie ED, Keefe KA, DiFrischia DS, Zigmond MJ (1989) Differential effect of stress on in vivo 
dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem. 52: 1655-1658 
3.  Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, 
Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. 
Am J Psychiatry 155: 761-767 
4.  Agid O, Shapira B, Zislin J, Ritsner M, Hanin B, Murad H, Troudart T, Bloch M, Heresco LU, Lerer B (1999) 
Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major 
depression, bipolar disorder and schizophrenia. Mol.Psychiatry 4: 163-172 
5.  Angrist B, Sathanathan G, Wilk S, Gershon S (1974) Amphetamine psychosis: behavioural and biochemical 
aspects. Journal of Psychiatry Research 11: 13-23 
6.  Arndt S, Alliger RJ, Andreasen NC (1991) The distinction of positive and negative symptoms. The failure of a 
two-dimensional model. Br J Psychiatry 158: 317-322 
7.  Arnold SE, Han LY, Clark CM, Grossman M, Trojanowski JQ (2000) Quantitative neurohistological features of 
frontotemporal degeneration. Neurobiol.Aging 21: 913-919 
8.  Bakshi VP, Geyer MA (1997) Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by 
prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol.Exp.Ther. 283: 666-674 
9.  Bebbington PE, Wilkins S, Jones P (1993) Life events and psychosis: initial results from the Camberwell 
Collaborative Psychosis study. British Journal of Psychiatry 162: 72-79 
10.  Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK (1985) Symptomatic and neuropsychological components 
of defect states. Schizophr.Bull. 11: 409-419 
11.  Bird ED, Spokes EG, Barnes J, MacKay AV, Iversen LL, Shepherd M (1977) Increased brain dopamine and 
reduced glutamic acid decarboxylase and choline acetyltransferase activity in schizophrenia and related 
psychoses. Lancet ii: 1157-1159 
12.  Bird ED, Spokes EG, Iversen LL (1979) Increased dopamine concentration in limbic areas of brain from 
patients dying with schizophrenia. Brain 102: 347-360 
13.  Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978) Prestimulus effects on human startle reflex in 
normals and schizophrenics. Psychopysiology 15: 339-343 
14.  Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, 
patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234-258 
 
 
 
 
18
15.  Braff DL, Grillon C, Geyer MA (1992) Gating and habituation of the startle reflex in schizophrenic patients. 
Arch.Gen.Psychiatry 49: 206-215 
16.  Braff DL, Swerdlow NR, Geyer MA (1999) Symptom correlates of prepulse inhibition deficits in male 
schizophrenic patients. American Journal of Psychiatry 156: 596-602 
17.  Breier A, Buchanan RW (1992) The effects of metabolic stress on plasma progesterone in healthy volunteers and 
schizophrenic patients. Life Sci. 51: 1527-1534 
18.  Brown G, Birley J (1968) Crises and life changes and the onset of schizophrenia. J.Health.Soc.Behav. 9: 203-214 
19.  Brown G, Birley J, Wing J (1972) Influences of family life on the course of schizophrenic disorders: A 
replication. Br.J.Psychiatr. 121: 241-258 
20.  Butzlaff RL, Hooley JM (1998) Expressed emotion and psychiatric relapse: a meta-analysis. Arch Gen Psychiatry 
55: 547-552 
21.  Carasso BS, Bakshi VP, Geyer MA (1998) Disruption in prepulse inhibition after alpha-1 adrenoceptor 
stimulation in rats. Neuropharmacology 37: 401-404 
22.  Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M (1996) Sensorimotor gating in boys with 
Tourette's syndrome and ADHD: preliminary results. Biol.Psychiatry 39: 33-41 
23.  Chrousos GP (1988) Mechanisms of Physical and Emotional Stress. Plenum Press, New York 
24.  Connell PH (1958) Amphetamine Psychosis, Maudsley Monograph No. 5 edn. Chapman & Hall, London 
25.  Cools AR, Brachten R, Heeren D, Willemen A, Ellenbroek B (1990) Search after neurobiological profile of 
individual-specific features of Wistar rats. Brain Res.Bull. 24: 49-69 
26.  Crow TJ, Baker HF, Cross AJ, Joseph MH, Lofthouse R, Longden A, Owen F, Riley GJ, Glover V, Killpack WS 
(1979) Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings. Br J Psychiatry 
134: 249-256 
27.  Cullinan WE, Herman JP, Battaglia DF, Akil H, Watson SJ (1995) Pattern and time course of immediate early 
gene expression in rat brain following acute stress. Neuroscience 64: 477-505 
28.  Dajas F, Barbeito L, Martinez-Pesquera G, Lista A, Puppo D, Puppo-Touriz H (1983) Plasma noradrenalin and 
clinical psychopathology in schizophrenia. Neuropsychobiology 10: 70-74 
29.  David AS, Lewis GH, Allebeck P, Andreasson S (1992) Urban-rural differences in place of upbringing and later 
schizophrenia. Schizophrenia Research 6: 101 
30.  Delfs JM, Zhu Y, Druhan JP, Aston-Jones GS (1998) Origin of noradrenergic afferents to the shell subregion of 
the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res. 806: 127-140 
31.  Dent GW, Smith MA, Levine S (2001) Stress-induced alterations in locus coeruleus gene expression during 
ontogeny. Brain Res Dev.Brain Res 127: 23-30 
32.  Depoortere R, Perrault G, Sanger DJ (1997) Some, but not all, antipsychotic drugs potentiate a low level of 
prepulse inhibition shown by rats of the Wistar strain. Behav.Pharmacol. 8: 364-372 
33.  Donaldson IM, Dolphin A, Jenner P, Marsden CD, Pycock C (1976) The involvement of noradrenaline in 
motor activity as shown by rotational behaviour after unilateral lesions of the locus coeruleus. Brain 99: 427-446 
34.  Ellenbroek, B. A. and Cools, A. R. Apomorphine susceptible and apomorphine unsusceptible rats differ in the 
amphetamine induced sensitization of alpha-receptors in the nucleus accumbens. Soc.Neurosci Abstr 334.4. 
1993.  
 
 
 
 
19
35.  Ellenbroek BA, Cools AR (2000) Animal models for the negative symptoms of schizophrenia. Behav.Pharmacol. 
11: 223-233 
36.  Ellenbroek BA, Cools AR (2002) Apomorphine susceptibility and animal models for psychopathology: genes 
and environment. Behav.Genet. 32: 349-361 
37.  Ellenbroek BA, Geyer MA, Cools AR (1995) The behavior of APO-SUS rats in animal models with construct 
validity for schizophrenia. J.Neurosci. 15: 7604-7611 
38.  Ellenbroek BA, Sluyter F, Cools AR (2000) The role of genetic and early enviromental factors in determining 
apomorphine susceptibility. Psychopharmacology Berl. 124-131 
39.  Elman I, Adler CM, Malhotra AK, Bir C, Pickar D, Breier A (1998) Effect of acute metabolic stress on pituitary-
adrenal axis activation in patients with schizophrenia. Am J Psychiatry 155: 979-981 
40.  Falkai P, Schneider-Axmann T, Honer WG (2000) Entorhinal cortex pre-alpha cell clusters in schizophrenia: 
quantitative evidence of a developmental abnormality. Biol Psychiatry 47: 937-943 
41.  Faraone S, Tsuang M (1985) Quantitative models of the genetic transmission of schizophrenia. Psychol.Bull. 98: 
41-66 
42.  Farley IJ, Price KS, McCullough E, Deck JH, Hordynski W, Hornykiewicz O (1978) Norepinephrine in chronic 
paranoid schizophrenia: above-normal levels in limbic forebrain. Science 200: 456-458 
43.  Feenstra MG, Botterblom MH, Mastenbroek S (2000) Dopamine and noradrenaline efflux in the prefrontal 
cortex in the light and dark period: effects of novelty and handling and comparison to the nucleus accumbens. 
Neuroscience 100: 741-748 
44.  Feenstra MG, Botterblom MH, van Uum JF (1995) Novelty-induced increase in dopamine release in the rat 
prefrontal cortex in vivo: inhibition by diazepam. Neurosci.Lett. 189: 81-84 
45.  Fendt M, Li L, Yeomans JS (2001) Brain stem circuits mediating prepulse inhibition of the startle reflex. 
Psychopharmacology 
46.  Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition 
models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156: 
117-154 
47.  Gil-Ad I, Dickerman Z, Amdursky S, Laron Z (1986) Diurnal rhythm of plasma beta endorphin, cortisol and 
growth hormone in schizophrenics as compared to control subjects. Psychopharmacology (Berl) 88: 496-499 
48.  Gomes UC, Shanley BC, Potgieter L, Roux JT (1980) Noradrenergic overactivity in chronic schizophrenia: 
evidence based on cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations. Br J Psychiatry 137: 
346-351 
49.  Gottesman I, Shields J (1982) Schzophrenia: The epigenetic puzzle. Cambridge Press, New York 
50.  Griffiths JD, Cavanaugh J, Held J, Oates JA (1972) Dextramphetamine: evaluation of psychomimetic properties 
in man. Archives of General Psychiatry 26: 97-100 
51.  Grillon C, Morgan CA, Southwick SM, Davis M, Charney DS (1996) Baseline startle amplitude and prepulse 
inhibition in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res. 64: 169-178 
52.  Heston L (1966) Psychiatric disorders in foster home reared children of schizophrenic mothers. Br.J.Psychiatr. 
112: 819-825 
53.  Hornykiewicz O (1986) Brain noradrenaline and schizophrenia. Prog.Brain Res 65: 29-39 
 
 
 
 
20
54.  Hutchison KE, Swift R (1999) Effect of d-amphetamine on prepulse inhibition of the startle reflex in humans. 
Psychophamacology 143: 394-400 
55.  Ihalainen JA, Riekkinen PJ, Feenstra MG (1999) Comparison of dopamine and noradrenaline release in mouse 
prefrontal cortex, striatum and hippocampus using microdialysis. Neurosci.Lett. 277: 71-74 
56.  Jakob H, Beckmann H (1986) Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J 
Neural Transm. 65: 303-326 
57.  Jones PB, Bebbington PE, Foerster A (1993) Premorbid social underachievement in schizophrenia: results from 
the Camberwell Collaborative Psychosis Study. British Journal of Psychiatry 163: 65-71 
58.  Kawahara H, Kawahara Y, Westerink BH (2001) The noradrenaline-dopamine interaction in the rat medial 
prefrontal cortex studied by multi-probe microdialysis. Eur.J Pharmacol. 418: 177-186 
59.  Kehne JH, Padich RA, McCloskey TC, Taylor VL, Schmidt CJ (1996) 5-HT modulation of auditory and visual 
sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. 
Psychopharmacology (Berl) 124: 95-106 
60.  Kemali D, Del Vecchio M, Maj M (1982) Increased noradrenaline levels in CSF and plasma of schizophrenic 
patients. Biol Psychiatry 17: 711-717 
61.  Klitenick MA, Taber MT, Fibiger HC (1996) Effects of chronic haloperidol on stress- and stimulation-induced 
increases in dopamine release: tests of the depolarization block hypothesis. Neuropsychopharmacology 15: 424-
428 
62.  Koch M (1999) The Neurobiology of Startle. Prog.Neurobiol. 59: 107-128 
63.  Koch M, Schnitzler HU (1997) The acoustic startle response in rats - circuits mediating evocation, inhibition and 
potentiation. Behav. Brain. Res. 89: 35-49 
64.  Koenigsberg H, Handley R (1986) Expressed emotion: From predictive index to clinical constructs. 
Am.J.Psychiatr. 143: 1361-1373 
65.  Kulhara P, Kota SK, Joseph S (1986) Positive and negative subtypes of schizophrenia. A study from India. Acta 
Psychiatr.Scand. 74: 353-359 
66.  Lake CR, Sternberg DE, van Kammen DP, Ballenger JC, Ziegler MG, Post RM, Kopin IJ, Bunney WE (1980) 
Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science 207: 331-333 
67.  Lammers CH, Garcia-Borreguero D, Schmider J, Gotthardt U, Dettling M, Holsboer F, Heuser IJ (1995) 
Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal 
controls: II. Biol Psychiatry 38: 803-807 
68.  Liddle PF (1987) The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. 
Br J Psychiatry 151: 145-151 
69.  Lindvall O, Bjorklund A (1983) Dopamine and norepinephrine containing neuron system: Their anatomy in the 
rat brain. In: Emson PC (ed) Raven Press, New York, pp 229-255 
70.  Liposits Z, Phelix C, Paull WK (1987) Synaptic interaction of serotonergic axons and corticotropin releasing 
factor (CRF) synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. A light and electron 
microscopic immunocytochemical study. Histochemistry 86: 541-549 
71.  Mackay AVP, Iversen LL, Lassor M, Spokes E, Bird E, Arregui A, Creese I, Snyder S (1982) Increased brain 
dopamine and dopamine receptors in schizophrenia. Arch.Gen.Psychiatry 39: 991-997 
72.  Mackeprang T, Kristiansen KT, Glenthoj BY (2002) Effects of antipsychotics on prepulse inhibition of the 
startle response in drug-naive schizophrenic patients. Biol Psychiatry 52: 863-873 
 
 
 
 
21
73.  Malla AK, Norman RM, Williamson P, Cortese L, Diaz F (1993) Three syndrome concept of schizophrenia. A 
factor analytic study. Schizophr.Res 10: 143-150 
74.  Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. 
Psychopharmacology Berl. 94: 507-514 
75.  Mednick SA, Machon RA, Huttunen MO, Bonett D (1988) Adult schizophrenia following prenatal exposure to 
an influenza epidemic. Arch Gen Psychiatry 45: 189-192 
76.  Nurse B, Russell VA, Taljaard JJ (1985) Effect of chronic desipramine treatment on adrenoceptor modulation of 
[3H]dopamine release from rat nucleus accumbens slices. Brain Res. 334: 235-242 
77.  O´Callaghan E, Sham P, Takei N, Glover G, Murray RM (1991) Schizophrenia after prenatal exposure to 1957 
A2 influenza epidemic. Lancet 337: 1248-1250 
78.  Ornitz EM, Hanna GL, de Traversay J (1992) Prestimulation-induced startle modulation in attention-deficit 
hyperactivity disorder and nocturnal enuresis. Psychophysiology Vol 29: 437-451 
79.  Owen F, Cross AJ, Crow TJ, Longden A, Poulter M, Riley GJ (1978) Increased dopamine receptor sensitivity in 
schizophrenia. Lancet ii: 223-226 
80.  Owen MJ, Lewis SW, Murray RM (1988) Obstetric complications and schizophrenia: a computed tomographic 
study. Psychol Med 18: 331-339 
81.  Peng RY, Mansbach RS, Braff DL, Geyer MA (1990) A D2 dopamine receptor agonist disrupts sensorimotor 
gating in rats. Implications for dopaminergic abnormalities in schizophrenia. Neuropsychopharmacology. 3: 211-
218 
82.  Plotsky PM (1987) Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-
portal circulation after activation of catecholaminergic pathways or central norepinephrine injection. 
Endocrinology 121: 924-930 
83.  Plotsky PM, Cunningham E-TJ, Widmaier EP (1989) Catecholaminergic modulation of corticotropin-releasing 
factor and adrenocorticotropin secretion. Endocr.Rev. 10: 437-458 
84.  Puglisi-Allegra S, Kempf E, Schleef C, Cabib S (1991) Repeated stressful experiences differently affect brain 
dopamine receptor subtypes. Life Sci. 48: 1263-1268 
85.  Rainbow TC, Parsons B, Wolfe BB (1984) Quantitative autoradiography of beta 1- and beta 2-adrenergic 
receptors in rat brain. Proc.Natl.Acad.Sci.U.S.A 81: 1585-1589 
86.  Ralph RJ, Varty GB, Kelly MA, Wang YM, Caron MG, Rubinstein M, Grandy DK, Low MJ, Geyer MA (1999) 
The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition 
produced by amphetamine in mice. J.Neurosci. 19: 4627-4633 
87.  Raz S, Raz N (1990) Structural brain abnormalities in the major psychoses: a quantitative review of the evidence 
from computerized imaging. Psychol Bull. 108: 93-108 
88.  Rots NY, Cools AR, Berod A, Voorn P, Rostene W, deKloet E (1996) Rats bred for enhanced apomorphine 
susceptibility have elevated tyrosine hydroxylase mRNA and dopamine D2-receptor binding sites in nigrostriatal 
and tuberoinfundibular dopamine systems. Brain Res. 710: 189-196 
89.  Rots NY, Cools AR, de Jong J, de Kloet E (1995) Corticosteroid feedback resistance in rats genetically selected 
for increased dopamine responsiveness [published erratum appears in J Neuroendocrinol 1995 Apr;7(4):280]. 
J.Neuroendocrinol. 7: 153-161 
90.  Saavedra JM, Torda T (1980) Increased brain stem and decreased hypothalamic adrenaline-forming enzyme after 
acute and repeated immobilization stress in the rat. Neuroendocrinology 31: 142-146 
 
 
 
 
22
91.  Saigusa T, Tuinstra T, Koshikawa N, Cools AR (1999) High and low responders to novelty: effects of a 
catecholamine synthesis inhibitor on novelty-induced changes in behaviour and release of accumbal dopamine. 
Neuroscience 88: 1153-1163 
92.  Sawaya MC, Dolphin A, Jenner P, Marsden CD, Meldrum (1977) Noradrenaline-sensitive adenylate cyclase in 
slices of mouse limbic forebrain: characterisation and effect of dopaminergic agonists. Biochem.Pharmacol. 26: 
1877-1884 
93.  Sawchenko PE, Swanson LW (1982) The organization of noradrenergic pathways from the brainstem to the 
paraventricular and supraoptic nuclei in the rat. Brain Res 257: 275-325 
94.  Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger L, Gabriel E, Reynolds GP, Touretellotte WW (1984) 
Bimodal distribution od dopamine receptor densities in brains of schizophrenics. Science 225: 728-731 
95.  Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T (1-11-2002) Correlation of plasma neurosteroid levels to the 
severity of negative symptoms in male patients with schizophrenia. Schizophr.Res 58: 69-74 
96.  Speciale SG, Crowley WR, O'Donoghue TL, Jacobowitz DM (1978) Forebrain catecholamine projections of the 
A5 cell group. Brain Res. 154: 128-133 
97.  Susser ES, Lin SP (1992) Schizophrenia after prenatal exposure to the Dutch hunger winter of 1944-1945. 
Archives of General Psychiatry 49: 938-988 
98.  Swerdlow NR, Braff DL, Masten VL, Geyer MA (1990) Schizophrenic-like sensorimotor gating abnormalities in 
rats following dopamine infusion into the nucleus accumbens. Psychopharmacology Berl. 101: 414-420 
99.  Swerdlow NR, Caine SB, Geyer MA (1992) Regionally selective effects of intracerebral dopamine infusion on 
sensorimotor gating of the startle reflex in rats. Psychopharmacology Berl. 108: 189-195 
100.  Swerdlow NR, Geyer MA (1998) Using an animal model of deficient sensorimotor gating to study the 
pathophysiology and new treatments of schizophrenia. Schizophrenia Bulletin 24: 285-301 
101.  Swerdlow NR, Geyer MA (1999) Neurophysiology and neuropharmacology of short lead interval startle 
modification. In: Dawson ME, Schell A, Boehmelt A. (eds) Startle modification: implications for neuroscience , 
and clinical science. Cambridge University Press, Cambridge, pp 114-133 
102.  Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: 
current knowledge and future challenges. Psychopharmacology (Berl) 156: 194-215 
103.  Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson (1995) Impaired prepulse inhibition of 
acoustic and tactile startle response in patients with Huntington's disease. J.Neurol.Neurosurg.Psychiatry 58: 192-
200 
104.  Takei N, Mortensen PB, Klaening U, Murray RM, Sham PC, O´Callaghan E, Munk-Jorgensen P (1996) 
Relationship between in utero exposure to influenza epidemics and risk of schizophrenia in Denmark. Biol 
Psychiatry 40: 817-824 
105.  Takei N, O´Callaghan E, Sham P, Glover G, Murray RM (1992) Winter birth excess in schizophrenia: its 
relationship to place of birth. Schizophrenia Research 6: 102 
106.  Tassin JP (1992) NE/DA interactions in prefrontal cortex and their possible roles as neuromodulators in 
schizophrenia. J Neural Transm.Suppl 36: 135-162 
107.  Tassin JP, Studler JM, Herve D, Blanc G, Glowinski J (1986) Contribution of noradrenergic neurons to the 
regulation of dopaminergic (D1) receptor denervation supersensitivity in rat prefrontal cortex. J Neurochem. 46: 
243-248 
 
 
 
 
23
108.  Teppema LJ, Veening JG, Kranenburg A, Dahan A, Berkenbosch A, Olievier C (17-11-1997) Expression of c-
fos in the rat brainstem after exposure to hypoxia and to normoxic and hyperoxic hypercapnia. J Comp Neurol. 
388: 169-190 
109.  Teunis MAT, Kavelaars A, Voest E, Bakker JM, Ellenbroek BA, Cools AR, Heijnen CJ (2002) Reduced tumor 
growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. 
FASEB J 16: 1465-1467 
110.  Tuinstra T, Cools AR (2000) High and low responders to novelty: effects of adrenergic agents on the regulation 
of accumbal dopamine under challenged and non-challenged conditions. Neuroscience 99: 55-64 
111.  van Kammen DP, Antelman S (1984) Impaired noradrenergic transmission in schizophrenia? Life Sci. 34: 1403-
1413 
112.  van Kammen DP, Gelernter J (1987) Biochemical instability in schizophrenia. In: Meltzer HJ (ed) 
Psychopharmacology, the third generation of Progress. Raven Press, New York, 
113.  van Kammen DP, Peters J, van Kammen WB, Nugent A, Goetz KL, Yao J, Linnoila M (1989) CSF 
norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry 26: 176-
188 
114.  Varty GB, Bakshi VP, Geyer MA (1999) M100907, a serotonin 5-HT2A receptor antagonist and putative 
antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. 
Neuropsychopharmacology 20: 311-321 
115.  Vaughn C, Leff J (1976) Influances of family and social factors on the course of psychiatric illness. Br.J.Psychiatr. 
129: 125-137 
116.  Wan FJ, Caine SB, Swerdlow NR (1996) The ventral subiculum modulation of prepulse inhibition is not 
mediated via dopamine D2 or nucleus accumbens non-NMDA glutamate receptor activity. Eur.J Pharmacol. 
314: 9-18 
117.  Weike AI, Bauer U, Hamm AO (2000) Effective neuroleptic medication removes prepulse inhibition deficits in 
schizophrenia patients. Biol.Psychiatry 47: 61-70 
118.  Whalley LJ, Christie JE, Blackwood DH, Bennie J, Dick H, Blackburn IM, Fink G (1989) Disturbed endocrine 
function in the psychoses. I: Disordered homeostasis or disease process? Br.J.Psychiatry 155: 455-461 
119.  Zhang WN, Bast T, Feldon J (2000) Microinfusion of the non-competitive N-methyl-D-aspartate receptor 
antagonist MK-801 (dizocilpine) into the dorsal hippocampus of wistar rats does not affect latent inhibition and 
prepulse inhibition, but increases startle reaction and locomotor activity. Neuroscience 101: 589-599 
 
 
 
 
 
24
 C h a p t e r  2  
REMOVAL OF SHORT-TERM ISOLATION STRESS DIFFERENTIALLY INFLUENCES 
PREPULSE INHIBITION IN APO-SUS AND APO-UNSUS RATS 
T. A. SONTAG, A. R. COOLS AND B. A. 
ELLENBROEK 
Department of Psychoneuropharmacology  
University of Nijmegen P.O.Box 9101 6500HB Nijmegen 
Behav.Brain Res (2003) 141: 171-175 
 
Abstract 
Epidemiological studies have reported that the risk of developing schizophrenia increases with the 
number of genes one shares with patients suffering from schizophrenia (Gottesman, 1991). In 
addition, stressful life events are known to increase the risk of developing schizophrenia 
(Ellenbroek, van-den Kroonenberg et al., 1998) resulting in the stress hypothesis of schizophrenia. 
Remarkably, stress increases the release of dopamine and noradrenaline in the nucleus accumbens, 
(Puglisi, Imperato et al., 1991), which links the stress hypothesis with the known dopamine 
hypothesis of schizophrenia. Additionally an increased dopamine transmission in the nucleus 
accumbens (nacc) is known to disturb prepulse inhibition (ppi) (Wan, Geyer et al., 1994), a 
phenomenon observed in, among others, schizophrenics (Braff and Geyer, 1990).  
Some years ago we have genetically selected two rat-lines which are marked by a high (APO-SUS) 
and by a low (APO-UNSUS) apomorphine susceptibility. Similar to schizophrenics the APO-SUS 
rat-line shows a reduced prepulse inhibition (Ellenbroek, Geyer et al., 1995). However, these data 
were obtained after a period of mild stress, namely a 24h period of social isolation. Mild stress 
changes the line specific differences of APO-SUS and APO-UNSUS rats. The stress pushes the 
APO-SUS rat in the direction of an APO-UNSUS and vice versa, especially as far as it concerns the 
dopamine and noradrenaline activity in the nucleus accumbens. (Cools, van den Bos et al., 
1991;Cools, Rots et al., 1994;Cools, Brachten et al., 1990;Roozendaal and Cools, 1994). Therefore, 
in the present paper we investigated the prepulse inhibition response in non-stressed, i.e. non-
isolated APO-SUS and APO-UNSUS rats. In agreement with this hypothesis, we found that 
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removal of the stress led to an increase of prepulse inhibition in the APO-SUS, but a decrease in 
the APO-UNSUS. 
 These data clearly shows that the prepulse inhibition is stress-dependent in APO-SUS and APO-
UNSUS rats. It is suggested that the differential stress-induced change in the dopaminergic and the 
noradrenergic system influences the reaction of APO-SUS and APO-UNSUS rats on prepulse 
inhibition.  
Introduction  
Epidemiological studies have shown that the risk of developing schizophrenia is in part determined 
by the number of genes shared with someone suffering from this psychiatric illness (Gottesman, 
1991;Prescott and Gottesman, 1993). However, although genes play a crucial role in developing 
schizophrenia further epidemiological studies have shown that environmental factors are also of 
crucial importance. Most notably stressful life events occurring early in life or at adult age have been 
reported to increase the risk of schizophrenia (Ellenbroek, van-den Kroonenberg, and Cools, 
1998). Schizophrenic patients show elevated noradrenaline and cortisol levels in plasma and 
cerebrospinal fluid (Meltzer, 1987), which might reflect an increased response to stress. Moreover, 
the cortisol response to a stressor is greatly increased in schizophrenic patients (Lammers, Garcia-
Borreguero et al., 1995). This data are in concordance with the stress-hypothesis of schizophrenia 
(Walker and Diforio, 1997). Stress can enhance the release of dopamine especially in the nucleus 
accumbens (Puglisi, Imperato, Angelucci, and Cabib, 1991), which might link the stress hypothesis 
to the well known dopamine hypothesis of schizophrenia. Interestingly, an increase of dopamine 
transmission in the nucleus accumbens disrupts prepulse inhibition (Wan, Geyer, and Swerdlow, 
1994), a phenomenon also observed in, among others, schizophrenic patients (Braff and Geyer, 
1990)  
These facts clearly show that a genetic predisposition and stress contribute to schizophrenia. 
Several years ago, we have developed two rat lines based on the differential susceptibility to the 
dopaminergic agonist apomorphine: The APO-SUS rats show a strong stereotyped gnawing 
response to apomorphine, whereas the APO-UNSUS rats show a very weak gnawing response to 
this dopaminergic agonist. We have been able to show that both genetic and early environmental 
factors underlie this line-specific difference in apomorphine-susceptibility (Ellenbroek, Sluyter et al., 
2000). Similar to schizophrenic patients, APO-SUS rats show a heightened response to stress (Rots, 
Cools et al., 1996) as well as a reduced prepulse inhibition  (Ellenbroek, Geyer, and Cools, 1995). 
However, this reduced prepulse inhibition has been observed in rats that were socially isolated, i.e. 
after a period of mild stress. As discussed elsewhere, mildly stressed APO-SUS rats are among 
26 
others characterised by a relatively high mesolimbic noradrenergic and dopamine D2 activity, 
whereas mildly stressed APO-UNSUS rats are, among others, characterized by a relatively low 
mesolimbic noradrenergic and dopaminergic D2 activity (Cools, van den Bos, Ploeger, and 
Ellenbroek, 1991;Cools, Rots, and de Kloet, 1994;Cools, Brachten, Heeren, Willemen, and 
Ellenbroek, 1990; Roozendaal and Cools, 1994). Given the fact that both noradrenaline and 
dopamine agonists reduce prepulse inhibition (Carasso, Bakshi et al., 1998), these data may explain 
the line-specific difference in prepulse inhibition. 
Interestingly, when APO-SUS and APO-UNSUS rats are not stressed, the APO-SUS rats show a 
relative low noradrenergic activity but the non-stressed APO-UNSUS rats show a relative high 
noradrenergic activity. This change of noradrenergic activity has an influence on the dopaminergic 
activity, since noradrenaline facilitates dopamine release in the nucleus accumbens (Cools, van den 
Bos, Ploeger, and Ellenbroek, 1991;Cools, Rots, and de Kloet, 1994;Cools, Brachten, Heeren, 
Willemen, and Ellenbroek, 1990;Roozendaal and Cools, 1994). If the line-specific differences in 
dopamine and/or noradrenaline are causally related to the differences in prepulse inhibition, one 
would expect that removal of stress decreases prepulse inhibition in APO-UNSUS rats (in parallel 
to the increase in noradrenaline and dopamine D2 activity), and increases it in APO-SUS (in parallel 
to the decrease in noradrenaline and dopamine D2 activity). The present study was designed to 
investigate the influence of removal of mild stress on prepulse inhibition performance in APO-SUS 
and APO-UNSUS rats. 
Material and Methods  
Animals  
All APO-SUS and APO-UNSUS rats were bred in the Central Animal Laboratory of the University 
of Nijmegen. They weighed between 200 and 250 g at the time of experiment and had water and 
food freely available except during the testing in the prepulse inhibition-boxes. They were housed 
with a maximum of three animals per cage (42 x 26 x 15 cm). The rooms were temperature-
controlled with a standard 12 L: 12 D cycle: lights on from 07:00 to 19:00 h.  
Pharmacogenetic selection 
Several years ago, Cools et al. started a breeding program to pharmacogenetically select APO-SUS 
and APO-UNSUS rats (Cools, Brachten, Heeren, Willemen, and Ellenbroek, 1990). The present 
experiments were performed with male APO-SUS and APO-UNSUS rats belonging to the 28th 
generation. APO-SUS rats are defined as animals born from an APO-SUS mother and father. 
Likewise, APO-UNSUS rats are defined as animals born from an APO-UNSUS father and mother.  
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Treatment 
We used two groups of animals. The control group was treated according to Ellenbroek et al. 
(Ellenbroek, Geyer, and Cools, 1995). They were individually housed one day before testing. The 
animals of the experimental group were housed in groups (2-3 animals per cage, 42 x 26 x 15 cm). 
Then, we had four groups of animals: Socially housed APO-SUS (N = 6), isolated APO-SUS 
(N=7), socially housed APO-UNSUS (N = 8) and isolated APO-UNSUS (N = 6). 
Prepulse inhibition of the acoustic startle response 
The prepulse inhibition experiments were performed in four acoustic startle chambers of San 
Diego Instruments. One cage consists of a plexiglas tube (8.2 cm in diameter, 25 cm in length) 
resting on a plastic frame. A piezoelectric accelerometer mounted under the tube detected and 
transduced the motion of the tube. Stimulus delivery was done using the SR-LAB software, via a 
speaker mounted 10 cm above the cylinder. The computer software also digitized, rectified, and 
recorded the response of the accelerometer; with 100 ms readings collected beginning at stimulus 
onset. Startle amplitude was defined as the average of 100 readings. The whole system was 
mounted within a sound-attenuating chamber. Throughout the startle session, a background noise 
of 70dB was maintained. The experiment started with a 5 min habituation session with background 
noise in the startle system. After this habituation period, ten blocks of five trials were delivered to 
measure prepulse inhibition. Each of these blocks consisted of one startle trial (120 dB, 20 ms 
broad band burst), one no-stimulus condition, and three different prepulse-startle pairing 
administered pseudorandomly. In these pairings, the prepulse was 3, 5, or 10 dB above background. 
These prepulse were always 20msec broadband burst and always followed by the 120 dB startle 
pulse 100 ms later. The interval between two trials was between 10 and 20 sec.  
The startle amplitude was calculated as the mean of 10 delivered startle trials. 
The degree of prepulse inhibition (in percentage) was calculated according to the formula 
 100 x 
 trialstartleon  amplitude startle
 trialsprepulses all ofmean 
- 100  
Statistics 
To evaluate the data of the startle response and prepulse inhibition a two-way ANOVA with the 
factors line and treatment was used. The Fisher’s LSD post-hoc test was performed when the two 
way ANOVA was significant with either line or treatment as factor 
Results 
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Effect on the startle response (Fig 2) 
Removal of social isolation did not affect the startle response in APO-SUS or APO-UNSUS rats. 
Statistical analyses revealed no significant treatment, line or interaction effect. 
  
Fig 2: Effect of stress-removal on the Startle Response: Removal of stress had no effect on the startle response in APO-SUS and 
APO-UNSUS rats. The values are means + SEM 
Effect on the prepulse inhibition in APO-SUS and APO-UNSUS Rats (Fig 3) 
As expected the removal of isolation stress had a differential effect in APO-SUS and APO-UNSUS 
rats (treatment x line :(F1,23 = 11.93; p = < 0.001); though the treatment had no overall effect (F1,23 
= 0.33; p = > 0.05). Removal of the stress increased the prepulse inhibition in APO-SUS rats 
(Fisher’s LSD post-hoc p = 0.05) and decreased it in the APO-UNSUS rats (Fisher’s LSD post-hoc 
p =0.008). 
The socially housed groups differed too, APO-SUS rats showed a greater prepulse inhibition than 
APO-UNSUS rats (F1,12 = 13,0 ; p = 0,004) whereas the isolated groups did not differ (F1,11 = 1,22 ; 
p = > 0.05). However, analysis of the effect of various intensities revealed that the isolated APO-
SUS rats had less prepulse inhibition than the isolated APO-UNSUS rats at 75 dB prepulse 
intensity. (F1,11 = 5.290; p = 0.042) (data not shown).  
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Fig 3: Effect of stress removal on the prepulse inhibition in APO-SUS and APO-UNSUS: Removal of stress increased the prepulse 
inhibition in the APO-SUS rats (* p < 0.05) and decreased it in the APO-UNSUS rats (***p < 0.01). Consequently the social housed 
APO-SUS and APO-UNSUS rats differ in prepulse inhibition (*** p < 0.01) 
Discussion 
This study shows that removal of isolation stress differentially affected the prepulse inhibition in 
APO-SUS and APO-UNSUS rats: In line with our earlier hypothesis, it increased the prepulse 
inhibition in APO-SUS rats and decreased it in APO-UNSUS rats. Data from earlier studies 
showed that mildly stressed APO-SUS rats had a reduced prepulse inhibition at certain prepulse 
inhibition intensities (Ellenbroek, Geyer, and Cools, 1995). This deficit in APO-SUS rats was found 
at 72 and 74 dB prepulse intensity. Since somewhat different prepulse intensities were used in the 
present study, the data are not fully comparable. Nonetheless, as in the study in 1995, the stressed 
APO-SUS rats show a significantly reduced prepulse inhibition at the lower prepulse intensities 
compared to APO-UNSUS rats. Due to a relatively large variance, this reduction was not 
statistically significant at 73 dB, but it was at 75 dB. 
More importantly, however, the findings of this study complement the earlier data by showing that 
stress is a significant factor in prepulse inhibition performance, at least in APO-SUS and APO-
UNSUS rats. So far, very few people have investigated the relationship between stress and prepulse 
inhibition. We have previously found that maternally deprived normal Wistar rats, which are 
characterized by an increased sensitivity to stress, show a reduction in prepulse inhibition 
(Ellenbroek, van-den Kroonenberg, and Cools, 1998). Likewise, CRH-over expressing mice show 
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reduction in prepulse inhibition (Dirks, Groenink et al., 2002). Previous papers have also shown 
that social isolation from rearing on leads to reductions in prepulse inhibition in several rat strains 
(Geyer, Wilkinson et al., 1993;Varty and Geyer, 1998), including Wistar rats (Ellenbroek and Cools, 
2000). However, these data cannot be compared to the present set of experiments, since isolation 
rearing involves a very long period of isolation (up to 8 weeks) and the timing of the isolation 
seems to be crucial, since similar long periods of isolation in adulthood do not affect prepulse 
inhibition (Wilkinson, Killcross et al., 1994). 
As described in the introduction, exposing APO-SUS and APO-UNSUS rats to a mild stressor has, 
among others, a differential effect on the noradrenergic activity at the level of mesolimbic alpha1 
adrenoceptors: it enhances the relatively low noradrenergic activity in APO-SUS rats, whereas it 
decreases the relatively high noradrenergic activity in APO-UNSUS rats. Because stimulation of 
alpha1 adrenoceptor activity is known to reduce prepulse inhibition (Carasso, Bakshi, and Geyer, 
1998) it is possible that the stress-induced change of noradrenergic activity plays an important role 
in regulating prepulse inhibition in APO-SUS and APO-UNSUS rats. Based on this change of 
noradrenergic activity it was predicted that the removal of isolation-induced stress results in an 
enhancement of prepulse inhibition in APO-SUS rats and in a reduction of prepulse inhibition in 
APO-UNSUS rats. Although this is precisely what was found, it is evident that future studies are 
required to prove that it is indeed the mesolimbic alpha1 adrenoceptor activity that mediates the 
effects of systemically administered alpha1 adrenoceptor agonists and antagonists on prepulse 
inhibition. The precise mechanism how noradrenaline disturbs the prepulse inhibition is not clear 
yet; however, mesolimbic noradrenaline is known, among others to facilitate the dopamine release 
in the nucleus accumbens (Cools, 1988). Several studies have shown that an increased dopamine 
activity in the nucleus accumbens also disturbs prepulse inhibition (Swerdlow, Braff et al., 1990). 
Given the role of mesolimbic dopamine in prepulse inhibition, these findings suggest that 
noradrenaline might influence the prepulse inhibition by changing the dopamine release in the 
nucleus accumbens. Independent of the precise mechanism of action that underlies the line-specific 
effects of isolation-induced stress on prepulse inhibition, the present study clearly shows that 
exposure (or removal) to stress has a differential effect on prepulse inhibition in APO-SUS and 
APO-UNSUS rats. 
Overall impact 
First, the present study shows that prepulse inhibition is not fully invariant in rats that have, among 
others, a genetic difference in the mesolimbic noradrenergic system; it is clearly under control of 
internal and/or environmental conditions. For, unchallenged APO-SUS rats are marked by an 
increased prepulse inhibition in comparison with challenged APO-SUS rats, whereas unchallenged 
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APO-UNSUS rats are marked by a decreased prepulse inhibition in comparison with challenged 
APO-UNSUS rats. As mentioned in the introduction, stress is a central factor in schizophrenia. 
Studies have found an elevated level of cortisol (Muck-Seler, Pivac et al., 1999) and noradrenaline 
(Meltzer, 1987) in blood and plasma of patients. Furthermore, elevated plasma noradrenaline 
correlates with positive symptoms, overall psychopathology and paranoid symptoms (Dajas, 
Barbeito et al., 1983;Hultman, Wieselgren et al., 1997;Leff, 1981). Moreover, schizophrenic patients 
have an enhanced cortisol response to stress, and stressful life events might precipitate a relapse 
(Walker, Diforio et al., 1999). Given this differential sensitivity of schizophrenic patients and 
controls to stress, the present data may have consequences for the assessment of prepulse 
inhibition in human studies. Moreover, stress may also be a confounding factor in prepulse 
inhibition studies in animals, especially when different strains are being investigated. 
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Abstract 
Many years ago we started to breed two lines of Wistar rats on the basis of their sensitivity to the 
dopaminergic agonist apomorphine, namely the APO-SUS and APO-UNSUS rats. Several 
experiments in our laboratory have shown that APO-SUS rats share features such as a reduced 
prepulse inhibition (ppi) and an impaired stress response with schizophrenic patients. Recent 
experiments in our laboratory have shown that mild stressors reduce prepulse inhibition in APO-
SUS rats and increase prepulse inhibition in APO-UNSUS rats. Since mild stressors are known to 
increase the normally low functional noradrenergic activity in APO-SUS rats, but to decrease the 
normally high functional noradrenergic activity in APO-UNSUS rats, these data suggest that 
increasing the functional noradrenaline activity reduces prepulse inhibition. Aim of the present 
study was to investigate whether noradrenergic agonists would indeed reduce prepulse inhibition in 
APO-SUS and APO-UNSUS rats. Moreover, since it is known that the sensitivity of postsynaptic 
adrenoceptor agonist is inversely related to the functional noradrenergic activity, we expected a 
stronger effect in non-stressed APO-SUS rats, compared to non-stressed APO-UNSUS rats. We 
found that the alpha1 agonist cirazoline dose-dependently decreased prepulse inhibition in non-
stressed APO-SUS rats, but not in non-stressed APO-UNSUS rats, an effect which could be 
reversed by the alpha1-antagonist prazosin. The beta2 adrenoceptors agonist clenbuterol on the 
other hand did not affect prepulse inhibition in either APO-SUS or APO-UNSUS rats, when tested 
under non-stressed conditions. Neither adrenergic agonist affected baseline startle amplitude in 
these rats. These data suggest that alpha1 but not beta2-adrenoceptors modulates prepulse inhibition 
in APO-SUS and APO-UNSUS rats. 
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Introduction  
Several years ago we started to genetically breed two lines of rats, marked by a high (APO-SUS) and 
low (APO-UNSUS) response to apomorphine, respectively. As described elsewhere in detail these 
animals are further characterized by several behavioural and neurochemical differences (Cools, 
Brachten et al., 1990; Cools, Rots et al., 1993; Cools and Gingras, 1998). The differences in 
dopaminergic sensitivity make these animals an interesting model for investigating illnesses that are 
related to this neurotransmitter, such as schizophrenia and addiction. Indeed, we have previously 
shown that APO-SUS rats share a number of features with schizophrenic patients, including a 
reduced prepulse inhibition (Ellenbroek, Geyer et al., 1995) an increased stress response (Rots, 
Cools et al., 1995; Kemali, Maj et al., 1985) an increase in mRNA for tyrosine hydroxylase (Rots, 
Cools et al., 1996) and a dominance of Th2 helper cells (Breivik, Sluyter et al., 2000). Furthermore 
the APO-SUS rats display a reduced tumour growth which is in line with the finding that 
schizophrenic patients are relative protected from cancer (Teunis, Kavelaars et al., 2002). The fact 
that the differences between APO-SUS and APO-UNSUS rats are not only due to genetic 
differences but are also regulated by (early) environmental factors (Ellenbroek, Sluyter et al., 2000) 
emphasizes the validity of APO-SUS rats as a model for schizophrenia, since it is well known that 
both genetic (Freedman, Adler et al., 1999; Joober, Benkelfat et al., 1999) and early environmental 
factors (Agid, Shapira et al., 1999) contribute to the aetiology of schizophrenia  
We have shown recently that the prepulse inhibition response of APO-SUS and APO-UNSUS rats 
is not invariant, but sensitive to mild stressors (Sontag, Cools et al., 2003a). In fact a short term 
social isolation reduces prepulse inhibition in the APO-SUS rats, but enhances it in APO-UNSUS 
rats. Mild stressors, such as social isolation, are also known to enhance the functional mesolimbic 
noradrenergic activity in APO-SUS rats and to reduce it in APO-UNSUS rats (Cools, Rots et al., 
1994; Cools and Gingras, 1998) Thus in a non-stressed situation, APO-SUS rats show a relatively 
low functional noradrenergic activity, and APO-UNSUS rats a relatively high functional 
noradrenergic activity in the forebrain (Cools, Brachten, Heeren, Willemen, and Ellenbroek, 1990; 
Cools and Gingras, 1998). Combining these data results in the notion that rats with a high 
functional noradrenergic activity, i.e. stressed APO-SUS and non-stressed APO-UNSUS rats, have 
a reduced prepulse inhibition, whereas rats with a low functional noradrenergic activity, i.e. non-
stressed APO-SUS and stressed APO-UNSUS rats, have an increased prepulse inhibition. Thus, 
the differential response of stressed and non-stressed APO-SUS and APO-UNSUS rats in the 
prepulse inhibition might be related to the mesolimbic noradrenergic tone of these animals. 
It is well know that the noradrenergic tone determines the sensitivity of postsynaptic alpha-and 
beta-adrenoceptors (Starke, 1981; Reisine, Chesselet et al., 1982). An increased noradrenaline tone 
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leads to a reduced sensitivity of postsynaptic receptors for adrenergic agonists, whereas a reduced 
noradrenaline tone leads to an increased sensitive of these receptors for adrenergic agonists. Aim of 
the present paper was to investigate to what extent noradrenergic agonists reduce prepulse 
inhibition in non-stressed APO-SUS and APO-UNSUS rats, and whether the effect depends on 
the noradrenergic tone. Since we used non-stressed rats, we expected that naïve APO-SUS rats, 
having a low functional noradrenergic activity at rest, to be more sensitive to adrenergic agonist 
than naïve APO-UNSUS rats, which have a high functional noradrenergic activity at rest.  
Materials and Methods 
Animals  
All APO-SUS and APO-UNSUS rats were bred in the Central Animal Laboratory of the University 
of Nijmegen. They weighed between 200 and 250 g at the time of the experiments and had water 
and food freely available, except during the testing in the prepulse inhibition-boxes. They were 
housed with a maximum of three animals per cage (42 x 26 x 15 cm). The rooms were temperature-
controlled with a standard 12 L: 12 D cycle: lights on from 07:00 to 19:00 h. All experiments were 
performed according to institutional, national and international guidelines for animals care and 
welfare. The rats were only used once in these experiments.  
Pharmacogenetic selection 
Several years ago, we started a breeding program to pharmacogenetically select APO-SUS and 
APO-UNSUS rats (Cools, Brachten, Heeren, Willemen, and Ellenbroek, 1990). The present 
experiments were performed with male APO-SUS and APO-UNSUS rats belonging to the 17th 
generation of the replication line that was started in 1995 (Ellenbroek, Sluyter, and Cools, 2000). 
APO-SUS rats are defined as animals born from an APO-SUS male and female. Likewise, APO-
UNSUS rats are defined as animals born from an APO-UNSUS male and female. The number of 
animals per group tested is shown in table 1 
Prepulse inhibition of the acoustic startle response 
The prepulse inhibition experiments were performed in four acoustic startle chambers of San 
Diego Instruments. (San Diego, USA). Each cage consisted of a plexiglas tube (8.2 cm in diameter, 
25 cm in length) resting on a plastic frame. A piezoelectric accelerometer mounted under the tube 
detected and transduced the motion of the tube. Stimulus delivery was done using the SR-LAB 
software, via a speaker mounted 10 cm above the cylinder. The computer software also digitized, 
rectified and recorded the response of the accelerometer; with 100 ms readings, collected at the 
beginning of stimulus onset. Startle amplitude was defined as the average of these 100 readings. 
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The whole system was mounted within a sound-attenuating chamber. Throughout the startle 
session, a background noise of 70dB was maintained.  
The experiment started with a 5 min habituation session with background noise (70 dB) in the 
startle system. After this habituation period, ten blocks of five trials were delivered to measure 
prepulse inhibition. Each of these blocks consisted of one startle trial (120 dB, 20 ms broad band 
burst), one no-stimulus condition and three different prepulse-startle pairing administered 
pseudorandomly. In these pairings, the prepulse was 3, 5 or 10 dB above background. These 
prepulses were always 20 ms broadband burst and always followed by the 120 dB startle pulse 100 
ms later. The interval between two trials was between 10 and 20 s.  
The startle amplitude was calculated as the mean of 10 delivered startle trials.  
The degree of prepulse inhibition (in percentage) was calculated according to the formula: 
 100 x 
 trialstartleon  amplitude startle
 trialsprepulses all ofmean 
- 100  
Treatment 
All rats were housed in groups of 2 or 3 rats until immediately before testing in the prepulse 
inhibition-boxes. In contrast to previous experiments these rats were not isolated one day prior to 
the experiment since we have demonstrated that this form of mild stress reduces prepulse 
inhibition in APO-SUS rats but increase it in APO-UNSUS rats (Sontag, Cools, and Ellenbroek, 
2003a).  
Drugs APO-SUS APO-UNSUS 
saline 9 9 
cirazoline (0.1mg/kg) 8 8 
cirazoline (0.5mg/kg) 7 7 
cirazoline (1.0mg/kg) 6 8 
clenbuterol (0.001mg/kg) 8 8 
clenbuterol (0.004mg/kg) 8 7 
clenbuterol (0.016mg/kg) 7 6 
clenbuterol (0.064mg/kg) 8 8 
prazosin (2.5mg/kg) and 
cirazoline (1.0mg/kg) 
8 - 
 
Table 1: number of animals per experiment 
Before testing they received an i.p. injection and were transferred to the prepulse inhibition boxes 
and testing started. The control animals were injected with saline (1ml/kg). We used two drugs in 
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different concentrations. The alpha1-adrenoceptor agonist cirazoline (Research Biochemical 
Incorporated, Natick MA USA) was given in the dosage 0.1, 0.5 and 1.0 mg/kg. These doses were 
chosen on the basis of the outcome of the study by Carasso et al. (Carasso, Bakshi et al., 1998) who 
showed that these doses were behaviourally active. The beta2-adrenoceptor agonist clenbuterol 
(Sigma, Schnelldorf Germany) was given in the dosage 0.001, 0.004, 0.016 and 0.064 mg/kg, 
namely doses that were found to be behaviourally active in rats (Dooley, Mogilnicka et al., 1983). 
For antagonizing the alpha1-adrenoceptor agonist cirazoline, the alpha1-antagonist prazosin (Sigma, 
Schnelldorf Germany) in the dosage of 2.5 mg/kg was used. This dose was chosen based on the 
study from Bakshi et al (Bakshi and Geyer, 1997) who showed that this dose is behavioural active. 
The antagonist was given twenty minutes prior to the agonist. All drugs were dissolved in saline and 
the injected volume was 1ml/kg. 
Statistics  
The data were analyzed separately for each line, because APO-SUS and APO-UNSUS rats are 
characterized by a diametrically opposite adrenergic activity in the brain during rest as well as during 
challenging conditions (Cools, Brachten, Heeren, Willemen, and Ellenbroek, 1990;Cools and 
Gingras, 1998). The data of the startle response and prepulse inhibition were analyzed with a 
univariate Analysis of Variance (ANOVA) with the factor treatment. The post-hoc tests were done 
with Fisher LSD test. A p-value of < 0.05 was considered to be significant.  
 
Fig 4: Effect of cirazoline on the Startle response: Cirazoline had no effect on startle response in APO-SUS and APO-UNSUS rats. 
The values are means ± S.E.M 
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Results 
Startle Response 
Cirazoline (Fig 4) 
Stimulation of the alpha1 adrenoceptors with cirazoline did not significantly alter the baseline startle 
response, neither in APO-SUS rats (Treat: F (3, 26) = 0.348; p = 0.791) nor in APO-UNSUS rats 
(Treat: F (3, 28) = 1.160; p = 0.343).  
Clenbuterol (Fig 5) 
Stimulation of the beta2 adrenoceptors with clenbuterol likewise did not alter the baseline startle 
amplitude in APO-SUS (Treat: F (4, 35) = 0.97; p = 0.983) or APO-UNSUS rats (Treat: F (4, 33) = 
2.297; p = 0.080), though there was a tendency for an increase at 0.004 mg/kg dose in the latter 
rats.  
 
Fig 5: Effect of clenbuterol on startle response: clenbuterol had no effect on startle response in APO-SUS and APO-UNSUS rats 
Cirazoline and Prazosin (Fig 6) 
The basal startle response after the combined treatment of prazosin and cirazoline was not 
different from either saline or cirazoline treatment alone (F (2,20) = 0.450 ; p > 0.05).  
Prepulse Inhibition  
Cirazoline (Fig 7) 
The effect of the alpha1-adrenoceptor agonist cirazoline on prepulse inhibition differed between 
APO-SUS and APO-UNSUS rats. Cirazoline dose-dependently reduced prepulse inhibition in 
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APO-SUS rats (Treat: F (3, 26) = 6.261; p = 0.002). Post-hoc analyses showed that the two highest 
doses (0.5 and 1.0 mg/kg) significantly differed from the saline control group. On the other hand, 
cirazoline did not significantly alter prepulse inhibition in APO-UNSUS rats (Treat: F (3, 28) = 2.266; 
p = 0.103), though inspection of Fig 7 shows that there was a clear tendency for a reduction at the 
highest dose (1.0 mg/kg).  
Clenbuterol (Fig 8) 
The beta2 adrenoceptor agonist clenbuterol had no effect on prepulse inhibition in APO-SUS 
(Treat: F (4, 35) = 1.593; p = 0.198) and APO-UNSUS rats (Treat: F (4, 33) = 0.466; p = 0.760). 
Cirazoline and Prazosin (Fig 9) 
The alpha1-antagonist prazosin antagonized the disruptive effect of cirazoline on prepulse 
inhibition in APO-SUS rats (F (2,20) = 18.090 ; p < 0.05). 
 
Fig 6: Effect of cirazoline on startle response after pre-treatment with prazosin 
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 Fig 7: Effect of cirazoline on the prepulse inhibition: Cirazoline did not change the prepulse inhibition in the APO-UNSUS rats, but 
reduced it dose-dependently in APO-SUS rats (0.5mg/kg, ***p = 0.01; 1.0 mg/kg, ***p < 0.01 
 
 
Fig 8: Effect of clenbuterol on prepulse inhibition: Clenbuterol did not change the prepulse inhibition in APO-SUS and APO-
UNSUS rats.  
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 Fig 9: The effect of cirazoline and prazosin on prepulse inhibition: Prazosin antagonised the effect of cirazoline on prepulse inhibition 
in APO-SUS rats ( ***p < 0.001; **p < 0.01; * p < 0.05 ; # p < 0.05 
Discussion 
The data of the present study clearly show that alpha1 adrenoceptor stimulation dose-dependently 
decreased prepulse inhibition in APO-SUS but not in APO-UNSUS rats, an effect that could be 
antagonized with the alpha1-antagonist prazosin. On the other hand, stimulation of the beta2- 
adrenoceptor did not affect prepulse inhibition in APO-SUS or APO-UNSUS rats. Neither 
adrenoceptor agonist affected baseline startle amplitude. 
The finding that the beta2 adrenoceptor agonist did not affect the baseline startle amplitude is in 
agreement with the study of Astrachan & Davis who also showed that beta-adrenoceptor agonists 
are ineffective in this respect (Astrachan and Davis, 1981). Our finding that the alpha1-
adrenoceptor agonist was ineffective in changing the baseline startle amplitude is somewhat 
surprising since the aforementioned authors found an increase in baseline startle amplitude after 
intrathecal application of phenylephrine. Even though we used the same dose range as Carasso et al 
(Carasso, Bakshi, and Geyer, 1998) who also found an increase in baseline startle amplitude, we did 
not find this effect in our APO-SUS and APO-UNSUS rats. It is at present difficult to explain 
these  discrepancies, though it should be noted that Carasso et al (1998) and Astrachan and Davis 
(1981) used Sprague Dawley rats, whereas we used APO-SUS and APO-UNSUS rats and distinct 
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strains are known to respond differently to drugs as far as it concerns prepulse inhibition (Kinney, 
Wilkinson et al., 1999).  
The main goal of this study was to investigate the effects of adrenergic agonists on prepulse 
inhibition. The data shows that the alpha1-adrenoceptor agonist cirazoline dose-dependently 
reduced prepulse inhibition in non-stressed APO-SUS rats. In non-stressed APO-UNSUS rats a 
tendency for a reduced prepulse inhibition was seen at the highest dose (1.0 mg/kg); however, the 
overall effect was not significant. The dose of 0.5 mg/kg was not effective in APO-UNSUS, 
whereas it was highly effective in APO-SUS rats. Thus non-stressed APO-SUS rats were more 
sensitive for the alpha1-adrenoceptor agonist cirazoline than non-stressed APO-UNSUS rats. This 
is in line with our hypothesis, mentioned in the introduction, that the effects of alpha agonists 
depend on the functional activity of the noradrenergic system, which differs between non-stressed 
APO-SUS and non-stressed APO-UNSUS rats. The relatively high functional noradrenergic 
activity in the non-stressed APO-UNSUS is accompanied by a relatively low adrenoceptor 
sensitivity for cirazoline, whereas the relatively low functional noradrenergic activity in the non-
stressed APO-SUS is accompanied by relatively high adrenoceptor sensitivity for cirazoline.  
In contrast to the alpha1 agonist, the beta2 agonist clenbuterol had no effect on prepulse inhibition. 
It is unlikely that this lack of effect was due to the dose range chosen. Dooley and colleagues have 
shown that these doses are behaviourally active (Dooley, Mogilnicka, Delini, Waechter, Truog, and 
Wood, 1983). Moreover, we have also found that theses doses are behaviourally active in our APO-
SUS and APO-UNSUS rats (Sontag, Cools et al., 2003b submitted). Thus it seems more likely that 
beta2 adrenoceptors do not contribute to the expression of prepulse inhibition.  
The neuronal mechanism by which alpha1 adrenoceptor agonists modulates prepulse inhibition is 
not clear yet. The noted differences in noradrenergic activity between APO-SUS and APO UNSUS 
rats are, among others, present in the nucleus accumbens (Nacc) (Cools, Brachten, Heeren, 
Willemen, and Ellenbroek, 1990; Tuinstra and Cools, 2000).The nucleus accumbens is known to 
play a crucial role in prepulse inhibition, since increasing the dopamine (D2) activity within this 
nucleus disrupts prepulse inhibition (Swerdlow, Mansbach et al., 1990;Wan and Swerdlow, 
1993;Wan, Geyer et al., 1994).  
As described elsewhere in detail stimulation of accumbal alpha1-adrenoceptors results in the 
inhibition of the dopamine activity at the level of a subtype of dopamine receptors that differ from 
the classic dopamine D1 and D2 receptors (Cools, van den Bos, Ploeger, and Ellenbroek, 1991). 
Because such a low dopamine activity at these receptors is always associated with a high dopamine 
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activity at the level of the accumbal, dopamine D2 receptors it might be this functional relation that 
gives rise to the cirazoline induced decrease in prepulse inhibition (Cools, van den Bos, Ploeger, 
and Ellenbroek, 1991). 
In summary, we found that non-stressed APO-SUS rats show a strong reduction in prepulse 
inhibition, after intraperitoneal application of the alpha1-adrenoceptor agonist cirazoline, while non-
stressed APO-UNSUS rats were much less sensitive to this drug. This is in agreement with the 
notion that non-stressed APO-SUS rats are characterized by a relatively low functional 
noradrenergic activity, and subsequently a relatively high sensitivity of the postsynaptic alpha1 
adrenoceptors for the agonist. Non-stressed APO-UNSUS rats, on the other hand, are 
characterized by a relatively high functional noradrenergic activity, and subsequently a relatively low 
sensitivity of the postsynaptic alpha1 adrenoceptors for the agonist. On the other hand stimulation 
of the beta2 adrenoceptors, by application of clenbuterol, had no effect on prepulse inhibition in 
either APO-SUS or APO-UNSUS rats. It is concluded that alpha1 but not beta2 adrenoceptors are 
involved in modulating prepulse inhibition.  
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Abstract 
As described elsewhere in detail the so called apomorphine susceptible (APO-SUS) and 
apomorphine unsusceptible (APO-UNSUS) rats are characterised by several behavioural and 
neurochemical differences. Furthermore APO-SUS rats share some symptoms with schizophrenic 
patients like a reduced prepulse inhibition (ppi). However recent studies showed that mild stress 
reduces prepulse inhibition in APO-SUS rats and increases it in APO-UNSUS rats. Parallel mild 
stress is known to increase the functional noradrenergic activity in APO-SUS and to decrease it in 
APO-UNSUS rats. Noteworthy, alpha1-adrenergic agonists were found to disrupt prepulse 
inhibition whereas alpha1-antagonists were found to increase prepulse inhibition. This strongly 
suggests that a high noradrenergic activity reduces prepulse inhibition whereas a low noradrenergic 
activity increases prepulse inhibition. In the present study we depleted central noradrenaline with 
the help of the neurotoxin DSP4 which destroy locus coeruleus (LC) terminals to investigate 
whether a decrease in noradrenergic activity leads to an increase in prepulse inhibition in APO-SUS 
and APO-UNSUS rats. The effects of DSP4 on prepulse inhibition were tested under non-stressed 
conditions and after exposing the rats to mild stress. We also investigated the effects of DSP4 on 
the adrenoceptor sensitivity with the help of counting the number of head-dips. DSP4 did not alter 
the prepulse inhibition in non-stressed rats. However DSP4 increased prepulse inhibition in 
stressed APO-UNSUS, but reduced it in stressed APO-SUS rats. Furthermore, the pre-treatment 
with DSP4 strengthened the effect of the alpha1 agonist cirazoline in reducing the number of head-
dips in APO-SUS rats. Such an effect was not seen in APO-UNSUS rats. Likewise, the pre-
treatment with DSP4 strengthened the effect of the alpha2 antagonist clonidine in reducing the 
number of head-dips in APO-UNSUS rats; again, such an effect was not seen in APO-SUS rats. 
These data indicate the development of supersensitive alpha1-adrenoceptors in the APO-SUS rats 
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 and the development of supersensitive alpha2 adrenoceptors in APO-UNSUS rats after DSP4 
treatment. In addition these data show that the alteration of prepulse inhibition in DSP4-treated 
APO-SUS and APO-UNSUS rats is dependent on mild stress. In conclusion these data give strong 
evidence that the locus coeruleus is somehow involved in modulating prepulse inhibition.  
Introduction 
The prepulse inhibition of the acoustic startle is a decrease in startle response that occurs when the 
startle stimulus is preceded by a weaker stimulus. Disturbances in this phenomenon have been 
found  in patients with neuropsychiatric diseases like Huntington’s disease (Swerdlow, Paulsen et 
al., 1995) and schizophrenia (Braff and Geyer, 1990). Several years ago we started breeding the so 
called apomorphine-susceptible (APO-SUS) and apomorphine-unsusceptible (APO-UNSUS) rats. 
Notably, the APO-SUS rats share several abnormalities with schizophrenic patients like an 
enhanced stress response (Rots, Cools et al., 1995), and a reduced prepulse inhibition and latent 
inhibition (Ellenbroek, Geyer et al., 1995). Recent data from our laboratory have shown that the 
degree of prepulse inhibition also depends on the level of stress. Thus a short term social isolation 
reduces prepulse inhibition in APO-SUS and increases it in APO-UNSUS rats (Sontag, Cools et al., 
2003a). In the past we have found that these rats differ both in their functional noradrenergic 
activity as well as in the reactivity of this system to mild stress. The non-stressed APO-SUS rats are 
marked by a relatively low functional noradrenergic activity whereas the non-stressed APO-UNSUS 
rats are marked by a relatively high functional noradrenergic activity. Exposure to a mild stressor 
increases the functional noradrenergic activity in the APO-SUS rats, but decreases it in the APO-
UNSUS rats (Cools, Brachten et al., 1990; Cools and Gingras, 1998). Taken these data together it 
appears that rats with a high functional noradrenergic activity (viz. stressed APO-SUS and non-
stressed APO-UNSUS rats) show a reduced prepulse inhibition, whereas rats with a low functional 
noradrenergic activity (viz. non-stressed APO-SUS and stressed APO-UNSUS rats) show an 
enhanced prepulse inhibition. In agreement with this, we have recently found that the alpha1-
adrenoceptor agonist cirazoline reduces prepulse inhibition in non-stressed APO-SUS, rats but not 
in non-stressed APO-UNSUS rats (Sontag, Cools et al., 2003b submitted).  
In the present paper we investigated whether a decrease in noradrenergic activity would lead to an 
increase in prepulse inhibition in APO-SUS and APO-UNSUS rats. For that purpose, we depleted 
the central noradrenergic system using the neurotoxin DSP4 (N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine). This neurotoxin is known to selectively destroy the noradrenergic terminals of 
the locus coeruleus (LC) fibres without affecting the serotonergic or dopaminergic fibres (Jonsson, 
Hallman et al., 1981). The effect on the peripheral noradrenergic system is reversible and returns to 
normal after approximately 7 to 10 days (Jonsson, Hallman, Ponzio, and Ross, 1981).  
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 We used four experimental groups to investigate the effect of DSP4 on prepulse inhibition. The 
effects under baseline conditions were investigated in non-stressed APO-SUS and APO-UNSUS 
rats. To investigate the effect of DSP4 under mildly stressful conditions we isolated the APO-SUS 
and APO-UNSUS rats one day prior to the prepulse inhibition experiment (Sontag, Cools, and 
Ellenbroek, 2003a). The prepulse inhibition experiments were performed 14 days after the 
administration of DSP4.  
Since DSP4 reduces the noradrenergic activity, we expected to see an increase in prepulse inhibition 
in the rats with a high functional noradrenergic activity (i.e. stressed APO-SUS and non-stressed 
APO-UNSUS rats). Less effect on prepulse inhibition was expected in the rats which already have a 
low functional noradrenergic activity (i.e. non-stressed APO-SUS and stressed APO-UNSUS rats). 
Surprisingly, we found a decrease in prepulse inhibition in stressed APO-SUS rats after DSP4 
treatment. Since the most likely explanation for this phenomenon is the development of 
supersensitive receptors, we decided to investigate whether DSP4 indeed induces a change in the 
sensitivity of the noradrenergic receptors using the adrenoceptor agonist-induced reduction in head 
dips (Dooley, Mogilnicka et al., 1983).  
Material and Methods  
Animals  
  APO-SUS Naïve (Sontag, Cools, and Ellenbroek, 
2003a) 
saline DSP4 
Non-isolated 6 6 6 
Isolated 7 7 6 
APO-UNSUS Naïve (Sontag, Cools, and Ellenbroek, 
2003a) 
saline DSP4 
Non-isolated 8 8 7 
Isolated 6 10 6 
 
Table 2: Amount of rats used 
All APO-SUS and APO-UNSUS rats were obtained from the Central Animal Laboratory of the 
University of Nijmegen. They weighed between 200 and 250 g at the time of experiment and had 
water and food freely available except during the testing. They were grouped housed (2-3 animals 
per cage) in temperature-controlled rooms with a standard 12 L: 12 D cycle: lights on from 0700 to 
1900 hr. All experiments were performed according to institutional, national and international 
guidelines for animal care and welfare. The number of animals used in each group is indicated in 
table 2 
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 Pharmacogenetic selection 
Several years ago we started a breeding program to pharmacogenetically select APO-SUS and 
APO-UNSUS rats (Cools, Brachten, Heeren, Willemen, and Ellenbroek, 1990). The present 
experiments were performed with naive male APO-SUS and APO-UNSUS rats belonging to the 
29th generation. APO-SUS rats are defined as animals born to an APO-SUS male and female; 
likewise APO-UNSUS rats are defined as animals born to an APO-UNSUS male and female.  
Treatment 
DSP4 Injection 
Non-isolated Group 
The rats received a single dose on DSP4 (Sigma-Aldrich, Steinheim Germany; 25 mg/ kg; 1ml / kg) 
injected i.p. The drug was dissolved in saline; consequently, the control animals received the same 
volume of saline. The dose was chosen on the basis of the study of Lapiz et al (Lapiz, Mateo et al., 
2000) who showed a significant reduction in noradrenaline content after DSP4 treatment. The 
animals stayed grouped housed in their home cages for two weeks, allowing the peripheral 
noradrenergic system to recover (Jonsson, Hallman, Ponzio, and Ross, 1981).  
Isolated Group 
The rats were treated similar to the rats of the “non-isolated group”, except that they were isolated 
in new cages one day prior to the prepulse inhibition experiment.  
Prepulse Inhibition of the acoustic startle response 
Two weeks after the administration of DSP4, the rats were tested for their performance in prepulse 
inhibition. The prepulse inhibition experiments were performed in acoustic startle chambers of San 
Diego Instruments (San Diego USA). Basically, the cage consists of a plexiglas tube (8.2 cm in 
diameter, 25 cm in length) resting on a plastic frame. A piezoelectric accelerometer mounted under 
the tube detected and transduced the motion of the tube. Stimulus delivery was done using the SR-
LAB software, via a speaker mounted 10 cm above the cylinder. The computer software also 
digitized, rectified and recorded the response of the accelerometer, with hundred 1 ms readings 
collected beginning at stimulus onset. Startle amplitude was defined as the average of 100 readings. 
The whole system was mounted within a sound attenuating chamber. Throughout the startle 
session a background noise of 70dB was maintained.  
The experiment started with a 5 min habituation period in the startle system with background 
noise. After this habituation period ten blocks of five trials were delivered to measure prepulse 
inhibition. Each of these blocks consisted of one startle trial (20 ms 120 dB broadband burst), one 
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 no-stimulus condition and three different prepulse-startle pairing administered pseudorandomly. In 
these pairings the prepulse was 3, 5 or 10 dB above background. The prepulses were 20 ms 
broadband burst, followed by a startle pulse 100 ms later. The interval between two trials was 
between 10 and 20 s.  
The startle amplitude was calculate as the mean of the 10 delivered startle trials  
The degree of prepulse inhibition (in percentage) was calculated according to the formula 
 100 x 
 trialstartleon  amplitude startle
 trialsprepulses all ofmean 
- 100  
Head-dips 
This test was based on the study of Dooley and colleagues. (Dooley, Mogilnicka, Delini, Waechter, 
Truog, and Wood, 1983). After injection of the drug, the rats were placed in a square box where the 
numbers of head-dips were detected automatically for 12 minutes. This box consists of a black 
plastic box of 70 x 70 cm. The bottom plate of this box is equipped with 32 holes. In the centre of 
the plate is a central platform (25 cm x 25 cm). The activity of the rats is measured with the help of 
infrared beams located at the side walls; 10 beams above the plate for measuring locomotor activity 
and another 12 beams underneath the plate for measuring the head-dips. This test was performed 
one week after the prepulse inhibition experiment. First we tried to replicate the experiment 
performed by Dooley and colleagues (Dooley, Mogilnicka, Delini, Waechter, Truog, and Wood, 
1983) with the alpha2 adrenoceptor agonist clonidine (Sigma, Steinheim Germany) in the dosage 
0.065 and 0.13 mg/kg. Since it is known from previous studies (Carasso, Bakshi et al., 1998; Sontag, 
Cools, and Ellenbroek, 2003b submitted) that especially the alpha1 adrenoceptors play a role in 
mediating prepulse inhibition, we also used the alpha1-adrenergic agonist cirazoline (Research 
Biochemical Incorporated, Natick MA USA) in the dosage 0.1 and 0.5 mg/kg to evaluate the DSP4 
induced changes in alpha1-adrenoceptor sensitivity. The doses were chosen on the basis of the 
outcome of our previous study (Sontag, Cools, and Ellenbroek, 2003b submitted) where we 
showed that these doses were behaviourally active.  
All drugs were dissolved in saline and given i.p. and the injected volume was 1ml/kg. The control 
groups were injected with the same volume of saline.  
Statistics 
The prepulse inhibition and startle response data were analyzed with a one-way analysis of 
variances (ANOVA) with the factor pre-treatment. For analysis the animals were separate in 
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 isolated and non-isolated and each line was analysed separately. This was done because of the 
known difference in stress sensitivity and the known difference in the noradrenergic activity of 
these rats. A p-value of < 0.05 was considered to be significant. 
The data of the head-dip experiment were analysed with a two-way analysis of variances. 
(ANOVA) with the factors pre-treatment (saline vs. DSP-4) and drug (saline vs. clonidine or 
cirazoline). The data were analysed separately for line and alpha-adrenergic drugs. The LSD-Fisher 
Test was used as post-hoc test. A p-value of < 0.05 was considered to be significant. 
Results  
Non-Isolated Group 
Startle Response (Fig 10) 
DSP4 did not significantly affect the startle amplitude in either APO-UNSUS rats (F 1,13 = 3.74; p > 
0.05) or APO-SUS rats (F 1,10 = 0.23; p > 0.05), though a notable (non-significant) reduction was 
found in the non-isolated DSP4-treated APO-UNSUS rats.   
 
Fig 10: The Treatment with DSP4 had no effect on the startle response in non-isolated rats.  
Prepulse inhibition (Fig 11) 
No significant effect of DSP4 treatment on prepulse inhibition in non-isolated APO-SUS (F 1,10 = 
0.25; p > 0.05) and non-isolated APO-UNSUS rats was found (F 1,13 = 0.083; p > 0.05).  
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Fig 11: The treatment with DSP4 had no effect on the prepulse inhibition in non-isolated rats 
Isolated Group 
Startle Response (Fig 12) 
DSP4 significantly reduced the startle response in isolated APO-SUS rats (F 1,11 = 6.59; p < 0.05), 
but not in isolated APO-UNSUS rats (F 1,14 = 0.08; p > 0.05). 
Prepulse Inhibition (Fig 13) 
DSP4 increased prepulse inhibition in the isolated APO-UNSUS rats (F 1,14 = 6.92; p < 0.05) and 
reduced prepulse inhibition in the DSP4-pretreated isolated APO-SUS rats, though this just missed 
significance (F 1,11 = 4.35; p = 0.06). 
Head-Dips  
Clonidine (Fig 14) 
Clonidine significantly reduced the number of head-dips in both APO-SUS (F5,26 = 10.29; p < 0.05) 
and APO-UNSUS rats (F5,39 = 9.67; p <0.05). At the lowest dose (0.065 mg/kg), clonidine 
significantly reduced the number of head-dips only in the DSP4 pre-treated (p < 0.01), but not in 
the saline pre-treated APO-UNSUS rats (p > 0.05). This dose did not significantly alter the number 
of head-dips in either DSP4 or saline pre-treated APO-SUS rats. The highest dose of clonidine 
reduced the number of head-dips in all animals.  
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Fig 12: The treatment with DSP4 reduced the startle response in isolated APO-SUS rats; * p < 0.05 
 
Fig 13: DSP4 increased the prepulse inhibition in isolated APO-UNSUS rats and showed a strong trend for a reduced prepulse 
inhibition in APO-SUS rats; * p < 0.05, # p = 0.06 
Cirazoline (Fig 15) 
The number of head-dips decreased in both APO-SUS (F 5,31 = 6.96; p < 0.01) and APO-UNSUS 
rats (F 5,38 = 6.53; p < 0.01) after cirazoline treatment. The lowest dose (0.1mg/kg) reduced the 
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 number of head-dips in DSP4 pre-treated APO-SUS rats only (p < 0.05) but not in saline pre-
treated APO-SUS rats (p > 0.05). The highest dose (0.5mg/kg) reduced the number of head-dips in 
both the saline (p < 0.01) and DSP4 pre-treated (p < 0.01) APO-SUS rats to a similar amount. In 
the APO-UNSUS rats, both the lowest and the highest dose reduced the number of head-dips to 
an equal amount in both saline and DSP-4 treated rats.  
 
Fig 14: clonidine reduced the head dips in both lines of rats. The lowest dose clonidine reduced the head dips only in DSP4 pre-
treated APO-SUS rats. The same dose had no effect in either saline or DSP4 pre-treated APO-SUS rats ; *** p < 0.001 
Discussion 
DSP4 did not affect prepulse inhibition (Fig 11) or the startle response (Fig 10) in non-isolated 
APO-SUS or APO-UNSUS rats. However, when the rats were isolated for one day DSP4 reduced 
the startle response in APO-SUS rats (Fig 13). The same treatment increased prepulse inhibition in 
APO-UNSUS rats and decreased it in APO-SUS rats. In addition, the lower dose of the alpha2-
agonist clonidine reduced the number of head-dips only in the DSP4 pre-treated APO-UNSUS 
rats, indicating supersensitive alpha2-adrenoceptors in these animals. In APO-SUS rats, on the other 
hand, the lowest dose of cirazoline reduced the head-dips only in the DSP4 pre-treated rats 
indicating the development of supersensitive alpha1-adrenoceptors in these rats. 
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Fig 15: The treatment with cirazoline decrease the head dips in both lines of rats. The lowest dose reduced the head dips in DSP4 
pre-treated APO-SUS rats but not in saline pre-treated APO-SUS rats. In APO-UNSUS rats both doses reduced the head dips to a 
similar amount independent from the pre-treatment; *** p < 0.001, * p < 0.05 
Prepulse Inhibition 
The data are not in complete agreement with our original hypothesis, namely that a reduction in 
noradrenaline levels would lead to an increase in prepulse inhibition, especially in animals with a 
high functional noradrenergic activity (i.c. non-isolated APO-UNSUS rats and isolated APO-SUS 
rats). In fact we found no effect of DSP4 on prepulse inhibition in non-isolated animals at all. 
When our data are compared to those of our previous study (Sontag, Cools, and Ellenbroek, 
2003a), it is clear that the prepulse inhibition in the non-isolated APO-SUS rats in the present 
experiment is relatively low (see  
Table 3). Likewise, the prepulse inhibition of the non-isolated APO-UNSUS animals is relatively 
high. The only difference between the two experiments is that the non-isolated animals in the 
present study received a saline injection two weeks prior to the prepulse inhibition experiment. 
Saline injections are known to induce a mild stress in animals (Radu, Brodin et al., 2001; Kiyatkin 
and Wise, 2001; Baumann, Elmer et al., 2000). Moreover, there is evidence that these saline 
injections can induce long-lasting alterations. Indeed, Antelman and colleagues have shown that 
such a saline injection increased the sensitivity to haloperidol two weeks after a single saline 
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 injection (Antelman, Kocan et al., 1986). Since mild stress is known to reduce prepulse inhibition in 
the APO-SUS and increase it the APO-UNSUS rat, (Sontag, Cools, and Ellenbroek, 2003a) we can 
only conclude that the saline injection indeed induced a mild stress in these animals, which lasted 
for at least 2 weeks. 
APO-SUS Naïve (Sontag, Cools, and Ellenbroek, 2003a) saline DSP4 
Non-isolated 61% 38% 47% 
Isolated 42% 46% 21% 
APO-UNSUS Naïve (Sontag, Cools, and Ellenbroek, 2003a) saline DSP4 
Non-isolated 25% 36% 33% 
Isolated 51% 54% 72% 
 
 Table 3: Effects on the prepulse inhibition 
One of the most intriguing findings of the present study is that depletion of noradrenaline with the 
neurotoxin DSP4 did not affect the prepulse inhibition in rats that were non-isolated, but altered it 
in animals that were isolated for 24 hr prior to the test (see Table 3). As discussed (Sontag, Cools, 
and Ellenbroek, 2003a), short term isolation also acts as a mild stressor. Since both the non-isolated 
and the isolated animals received an injection two weeks prior to the experiment, this strongly 
suggests that the stress of the injection differs from the stress of the isolation, since DSP-4 affected 
the prepulse inhibition only in the isolated animals. 
It has been shown that noradrenaline, especially at level of the alpha1-adrenoceptors regulate 
prepulse inhibition: an increase in noradrenergic activity decreases prepulse inhibition (Sontag, 
Cools, and Ellenbroek, 2003b submitted; Carasso, Bakshi, and Geyer, 1998) whereas a decrease in 
noradrenergic activity increases prepulse inhibition (Depoortere, Perrault et al., 1997). The 
treatment with DSP4 reduces the noradrenergic activity by destroying the terminals of the locus 
coeruleus; therefore we expected to find an increased prepulse inhibition after this treatment. The 
increased prepulse inhibition found in the isolated APO-UNSUS rats fits perfectly with this 
expectation, indicating that the noradrenergic activity of the locus coeruleus is involved in 
modulating the prepulse inhibition. However, DSP4 was found to decrease the prepulse inhibition 
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 in isolated APO-SUS rats, namely a phenomenon that occurs after an increase rather than a 
decrease in the noradrenergic activity.  
Dooley and colleagues have reported a significant reduction in the number of head-dips in DSP4 
treated rats after the injection of the alpha2 antagonist clonidine (Dooley, Mogilnicka, Delini, 
Waechter, Truog, and Wood, 1983). Moreover, they showed that DSP4 treatment can indeed 
induce supersensitivity, at least with respect to the alpha2 adrenoceptors (Dooley, Bittiger et al., 
1983). In agreement with Dooley and colleagues we found that the highest dose of clonidine 
reduced the number of head-dips in both APO-SUS and APO-UNSUS rats, independent of the 
pre-treatment. However the low dose reduced the number of head-dips only in the DSP4 pre-
treated but not the saline pre-treated APO-UNSUS rats, indicating increased alpha2-adrenoceptor 
sensitivity. From previous studies it is known that the alpha1-adrenoceptor (Sontag, Cools, and 
Ellenbroek, 2003b submitted), rather than the alpha2-adrenoceptor is involved in modulating 
prepulse inhibition (Abduljawad, Langley et al., 1997; Kehne, Padich et al., 1996). Thus we used the 
alpha1-adrenoceptor agonist cirazoline to investigate the changes in adrenoceptor sensitivity. The 
lowest dose of cirazoline reduced the head-dips in the DSP4 pre-treated but not in the saline pre-
treated APO-SUS rats, indicating supersensitive alpha1-adrenoceptors in these rats. In APO-
UNSUS rats cirazoline reduced the head-dips to an equal amount in both saline and DSP4-
pretreated rats indicating the same receptor sensitivity in both treatment groups.  
APO-SUS Naïve (Sontag, Cools, and Ellenbroek, 2003a) saline DSP4 
Non-isolated 1079.7 1229.5 1154.3 
Isolated 705.7 1947.4 825.0 
APO-UNSUS Naïve (Sontag, Cools, and Ellenbroek, 2003a) saline DSP4 
Non-isolated 639 1434.9 730.6 
Isolated 776.0 1527.3 1402.8 
 
Table 4: Effects on the Startle response 
This increased sensitivity on the basis of the alpha1-adrenoceptors might explain the unexpected 
finding of a reduced prepulse inhibition in isolated DSP4 pre-treated APO-SUS rats. Stress is 
known to increase the functional noradrenergic activity in these rats. The treatment with DSP4 
destroys locus coeruleus terminals selectively, therefore other noradrenergic sources like the 
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 tegmental cell system or the medullary group are still active. In addition it can not be fully excluded 
that some locus coeruleus neurons have survived the treatment. Thus it may well be that the 
reduced prepulse inhibition found in these rats was caused by an increase in functional 
noradrenergic activity in combination with supersensitive alpha1-adrenoceptors.  
Startle Response 
The noradrenergic activity can also influence the startle response. The treatment with DSP4 
reduced the startle response in isolated APO-SUS rats. This finding is in line with the study from 
Adams and colleagues (Adams and Geyer, 1981); they found that lesioning of the locus coeruleus 
reduced the startle response. Both sets of data suggest that the reduction of the noradrenergic 
activity from the locus coeruleus reduce the startle response. However we discussed above that the 
reduction in prepulse inhibition in these rats can best be explained by an increased noradrenergic 
activity at the level of the alpha1-adrenoceptors. Thus these results suggest that the startle response 
and the prepulse inhibition are modulated by different adrenoceptors. In agreement with this, it was 
found that the alpha2-adrenoceptor agonist clonidine (Davis, Cedarbaum et al., 1977), but not the 
alpha1 antagonist prazosin (Depoortere, Perrault, and Sanger, 1997) reduced the basal startle 
amplitude.  
It should be noted that the startle response in the present experiments was quite high when 
compared to that found in our previous study (see Table 2). However, the rats were treated slightly 
different in these two studies. In the previous study the rats that were used for measuring startle 
response weighted between 200 and 250 g. In the present study the rats weighted between 200 and 
250 g when they were injected with DSP4 or saline respectively. Since the peripheral noradrenergic 
system has to recover from this treatment we waited two weeks before measuring the startle 
response (see Material and Methods). Therefore the rats in the present experiment were heavier 
than the ones used in our previous study. Because the startle amplitude positively correlates with 
weight (Schaeffer, 1987; Hall, 1984; Blaszczyk and Tajchert, 1996), we speculate that differences in 
weight underlie the noted differences in startle amplitudes. 
In conclusion  
The present data show that lesioning of the noradrenergic neurotransmission using the neurotoxin 
DSP4 differentially alters the prepulse inhibition in APO-SUS and APO-UNSUS rats. Thus it 
reduced the prepulse inhibition in isolated APO-SUS but increased it in isolated APO-UNSUS rats. 
Moreover, we could show that the behavioural alterations after DSP4 pre-treatment critically 
depend upon the level of stress of these rats. Thus DSP4 did not affect prepulse inhibition in non-
isolated (non-stressed) rats but altered it in isolated (stressed) APO-SUS and APO-UNSUS rats. 
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 Finally we could show that DSP4 treatment induced supersensitivity of the alpha1-adrenoceptors in 
APO-SUS rats and of alpha2-adrenoceptors in APO-UNSUS rats. In summary these data show that 
the noradrenergic terminals of the locus coeruleus (which are selectively destroyed by DSP4) 
modulate the prepulse inhibition in APO-SUS and APO-UNSUS rats, but that the effect depends 
on the level of stress of these animals.   
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Abstract 
Recent experiments in our laboratory suggested that the noradrenergic activity modulates the 
performance in prepulse inhibition in rats. However the mechanism by which noradrenaline 
reduces prepulse inhibition is unclear. Noradrenaline is known to control dopamine release in the 
nucleus accumbens and several studies have shown that the increase in accumbal dopamine reduce 
prepulse inhibition. Therefore we hypothesised that increased noradrenergic activity in the nucleus 
accumbens contributes to reductions in prepulse inhibition. In addition according to the gaiting 
theory by Cools and colleagues noradrenaline controls the information input from the basolateral 
amygdala and hippocampus to the nucleus accumbens, structures that have been identified to 
modulate prepulse inhibition. We implanted cannulas in the nucleus accumbens of rats in order to 
test the effects of the beta2- adrenoceptor agonist isoproterenol, the alpha1 adrenoceptor agonist 
phenylephrine and the alpha1 adrenoceptor antagonist phentolamine, drugs that are known to 
control accumbal dopamine release and control the information input to the nucleus accumbens. 
We found that none of the drugs given separately was able to alter the prepulse inhibition. 
However when given isoproterenol and phentolamine together the prepulse inhibition was 
significantly reduced. Although the mechanism is not fully understood these data show that the 
noradrenergic activity in the nucleus accumbens modulates prepulse inhibition. 
Introduction 
In patients suffering from neuropsychiatric diseases like Huntington’s disease (Swerdlow, Paulsen et 
al., 1995) and schizophrenia (Braff and Geyer, 1990) a reduced prepulse inhibition was found. This 
phenomenon refers to a decrease in startle response that occurs when the startle stimulus is 
preceded by a weaker stimulus. Recent experiments in our laboratory showed that environmental 
 61
 factors like mild stress modulate prepulse inhibition in apomorphine susceptible (APO-SUS) and 
apomorphine unsusceptible (APO-UNSUS) rats. Thus a single short-term social isolation was 
found to reduce prepulse inhibition in APO-SUS rats but to increase it in APO-UNSUS rats 
(Sontag, Cools et al., 2003a). Mild stress is known to increase the functional noradrenergic activity 
in APO-SUS rats but decrease it in APO-UNSUS rats (Cools, Brachten et al., 1990; Cools and 
Gingras, 1998). In addition the alpha1-agonist cirazoline was found to reduce prepulse inhibition in 
non-stressed APO-SUS rats, but not in non-stressed APO-UNSUS rats (Sontag, Cools et al., 2003b 
submitted) a finding that is in line with the study by Carasso and colleagues (Carasso, Bakshi et al., 
1998). Furthermore it was found that the destruction of locus coeruleus (LC) terminals with the 
selective neurotoxin DSP4 increased prepulse inhibition in stressed APO-UNSUS (Sontag, Cools et 
al., 2003c submitted). These data suggest that a high noradrenergic activity is associated with a 
reduction in prepulse inhibition and that a low noradrenergic activity is associated with an increase 
in noradrenergic activity. However the mechanism by which noradrenaline disrupts prepulse 
inhibition is still unclear.  
The locus coeruleus sends noradrenergic fibers to, among others, the nucleus accumbens 
(Cedarbaum and Aghajanian, 1978), a structure often implicated in the modulation of prepulse 
inhibition for (review see Swerdlow, Geyer et al., 2001). Thus, an increase in dopamine activity 
within this nucleus was found to disrupt prepulse inhibition (Swerdlow, Geyer, and Braff, 2001; 
Swerdlow, Caine et al., 1992; Wan and Swerdlow, 1993; Reijmers, Vanderheyden et al., 1995; 
Kretschmer and Koch, 1998). Interestingly, noradrenaline is known to control the dopamine 
release in the nucleus accumbens. This function is associated with regulating the information input 
of the basolateral amygdala (BLA) and the hippocampus into the nucleus accumbens. The gating 
theory by Cools and colleagues (Cools, van den Bos et al., 1991) states that activation of the beta2-
adrenoceptors blocks the information input of the hippocampus closing thereby the hippocampal 
gate. This is always associated with an increase in dopamine activity at the level of the D2 receptors. 
On the other hand inhibition of the alpha1-adrenoceptors blocks the information input from the 
basolateral amygdala (BLA) closing thereby the amygdala gate. This is always associated with an 
increase in dopaminergic activity at the level of a subtype of dopamine receptor that differs from 
the classical D1 and D2 receptors (Cools, van den Bos, Ploeger, and Ellenbroek, 1991). Recently, 
using the microdialysis technique, Tuinstra and colleagues showed that stimulation of beta2 and 
inhibition of alpha1 adrenoceptors increase the release of accumbal dopamine (Tuinstra and Cools, 
2000). Remarkably, also the stimulation of accumbal alpha1-adrenoceptors was found to increase 
accumbal dopamine. It was concluded that the agonist acts indirectly at the presynaptic site thereby 
inhibiting the release of noradrenaline from its terminal and subsequently disinhibits the release of 
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 dopamine. The antagonist has a direct effect by inhibiting the postsynaptic receptors on the 
corresponding dopamine terminals thereby facilitating the release of dopamine. 
Given the fact that noradrenaline regulates the accumbens dopamine release, and that accumbal 
dopamine plays a crucial role in prepulse inhibition (Swerdlow, Geyer, and Braff, 2001), we 
hypothesised that the accumbal noradrenaline transmission is involved in modulating prepulse 
inhibition. In order to investigate the effect of noradrenaline in the nucleus accumbens we locally 
applied alpha1 or beta2 adrenoceptor agents and studied their effect on prepulse inhibition. Because 
activation of the beta2-adrenoceptors enhances the release of mesolimbic dopamine at the level of 
the D2 receptors we expected to find a decrease in prepulse inhibition after intra-accumbal 
application of the beta2 antagonist isoproterenol. Other studies (Sontag, Cools, and Ellenbroek, 
2003b submitted; Carasso, Bakshi, and Geyer, 1998; Varty, Bakshi et al., 1999) indicated that 
especially the alpha1-adrenoceptors mediate prepulse inhibition. Therefore we also tested the 
alpha1-agonist phenylephrine and the alpha1-antagonist phentolamine since both drugs increase 
accumbal dopamine. According to the gaiting theory there are two distinct dopamine systems in the 
nucleus accumbens. By the combined administration of isoproterenol and phentolamine we tried to 
activate these two systems.  
Materials and Methods 
Animals  
All male Wistar rats were obtained from the Central Animal Laboratory of the University of 
Nijmegen. They weighed between 200 and 250 g at the time of experiment and had water and food 
freely available except during the experiment. They were grouped housed (2-3 animals per cage) in 
temperature-controlled rooms with a standard 12 L: 12 D cycle: lights on from 0700 to 1900 hr. All 
experiments were performed according to institutional, national and international guidelines for 
animals care and welfare. 
Stereotactic Operation  
The rats were anaesthetized with sodium pentobarbital (60mg/kg, i.p., Narcovet®) and placed in a 
stereotaxic apparatus. A guide cannula (5.5 mm in length, 0.65 mm outer diameter, 0.3 mm inner 
diameter), was aimed at the right and left nucleus accumbens according to previously described 
procedures (Saigusa, Tuinstra et al., 1999). The following coordinates were used: anterior, 10.6 mm; 
lateral, 1.5 mm and vertical, 3.5 mm according to the atlas of Paxinos and Watson (Paxinos and 
Watson, 1986). The cannula was angled 10° laterally. The cannulas were fixed on to the skull with 
the use of stainless steel screws and dental cement. The guide cannula contained an inner cannula 
to prevent infections as well as occlusions. The rats were placed in single cages and were allowed to 
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 recover from surgery for the next two weeks. To reduce the stress of injection, the animals were 
habituated to the injection procedure. Three days before the start of the experiment the animals 
were handled, the next day the screws of the cannulas were opened and one day prior to the 
prepulse inhibition test the injection itself was simulated by the use of an empty Hamilton syringe.  
Treatment and drugs  
Immediately before placing the rats in the prepulse inhibition chamber the rats received a bilateral 
injection in the nucleus accumbens. The injection depth was 12 mm. We used the beta2-
adrenoceptor agonist isoproterenol (Sigma, Schnelldorf Germany) in the doses of 0.5µg and 1µg; 
the alpha1 adrenoceptor agonist phenylephrine (Sigma Schnelldorf Germany) was given in the 
doses of 3µg, 5µg and 10µg. Furthermore we used the alpha1-antagonist phentolamine (Sigma 
Schnelldorf Germany) in the dose 2.5 µg. The doses were chosen on the basis of the studies from 
Tuinstra and colleagues (Tuinstra and Cools, 2000). Based on the outcome of the experiments we 
further used a combination of 1µg isoproterenol and 2.5µg phentolamine. All drugs were dissolved 
in saline and applied in a volume of 0.5µl per side. The control rats were injected with saline and all 
rats were used only once.  
Prepulse Inhibition of the acoustic startle response 
Two weeks after the operation the rats were placed in the experimental room and had 30 minutes 
to habituate. The prepulse inhibition experiments were performed in an acoustic startle chamber of 
San Diego Instruments. Basically, the cage consists of a plexiglas tube (8.2 cm in diameter, 25 cm in 
length) resting on a plastic frame. A piezoelectric accelerometer mounted under the tube detected 
and transduced the motion of the tube. Stimulus delivery was done using the SR-LAB software, via 
a speaker mounted 10 cm above the cylinder. The computer software also digitized, rectified and 
recorded the response of the accelerometer, with 100 1 ms readings collected beginning at stimulus 
onset. Startle amplitude was defined as the average of 100 readings. The whole system was 
mounted within a sound attenuating chamber. Throughout the startle session a background noise 
of 70dB was maintained.  
The experiment started with a 5 min habituation session in the startle system with background 
noise. After this habituation period ten blocks of five trials were delivered to measure prepulse 
inhibition. Each of these blocks consisted of one startle trial (120 dB), one no-stimulus condition 
and three different prepulse-startle pairing administered pseudorandomly. In these pairings the 
prepulse was 3, 5 or 10 dB above background. These prepulse were always 20 ms broad band burst 
and always followed by startle pulse 100 ms later. The interval between two trials was between 10 
and 20 sec.  
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 The startle amplitude was calculate as the mean of 10 delivered startle trials  
The degree of prepulse inhibition (in percentage) was calculated according to the formula 
 100 x 
 trialstartleon  amplitude startle
 trialsprepulses all ofmean 
- 100  
Histology 
After testing the rats in the prepulse inhibition they were deeply anaesthetized with pentobarbital 
(60mg/kg, i.p., Narcovet®) and perfused intracardially with 4% formaldehyde solution. The brains 
were removed and postfixed in the same fixative for at least 24h. Vibratome sections (100µm) were 
cut out to determine the location of the injection.  
 
Fig 16: Placement of cannulas 
Statistics  
The prepulse inhibition and startle response data were analysed with a one-way analysis of variances 
(ANOVA) with the factor dose. Post-hoc analyses were done with the LSD-Fisher Test. A p-value 
of < 0.05 was considered to be significant. Each drug was analysed separately.  
Results: 
Histology  
Placement of cannulas (Fig 16) 
Only rats with a correct placement of the cannula were included in the analysis. In total 57 rats were 
operated, 9 rats have been taken out because the placement was incorrect.  
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 Fig 16 shows the placement of the cannulas of the rats that were analysed.  
Startle:  
Isoproterenol (Fig 17) 
The beta2-adrenoceptor agonist isoproterenol induced an increase in the startle response (F 2,18 = 
18.57 ; p < 0.05) with the highest dose (1µg) being significantly larger than that seen in the saline 
control (p < 0.001).  
 
Fig 17: startle response after accumbal injection of isoproterenol. Only the highest dose of isoproterenol increased the startle 
significantly; ** p < 0.01, *** p < 0.001  
Phenylephrine and Phentolamine (Fig 18) 
Neither the alpha1-adrenoceptor agonist phenylephrine nor the alpha1-antagonist phentolamine 
significantly altered the startle response (F 3,25 = 2.75 ; p > 0.05).  
Combination of alpha-antagonist and beta agonist (Fig 19) 
The accumbal injection of isoproterenol and phentolamine did not alter the startle response 
compared to saline injection (F 3, 24 = 7.98; p < 0.001; posthoc p > 0.05).  However compared to 
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 isoproterenol, the combined injection of isoproterenol and phentolamine significantly reduced the 
startle (p < 0.01) 
 
Fig 18: Startle response after accumbal injection of alpha-adrenergic drugs 
Prepulse inhibition 
Isoproterenol (Fig 20) 
The local application of the beta2 agonist isoproterenol into the nucleus accumbens had no effect 
on the prepulse inhibition (F 2,18 = 1.83 ; p > 0.05)  
Phenylephrine and Phentolamine (Fig 21) 
After local application of the alpha1 agonist phenylephrine or the alpha1 antagonist phentolamine 
into the nucleus accumbens the prepulse inhibition was not significantly altered (F 3,25 = 1.31 ; p > 
0.05) 
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Fig 19: startle response after accumbal injection of adrenergic drugs: The increase in startle after isoproterenol was blocked by 
phentolamine. *** p < 0.001 ; ## p < 0.01, ### p < 0.001 against isoproterenol 1µg   
Combination of alpha-antagonist and beta agonist (Fig 22) 
In contrast to the single injection of either phentolamine or isoproterenol, the combined 
administration of phentolamine and isoproterenol induced a significant reduction in prepulse 
inhibition (F 3,24 = 3.30 ; p < 0.05).  
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Fig 20: PPI after accumbal injection of isoproterenol  
Discussion 
The present data show that stimulation of accumbal adrenoceptors differentially modulates startle 
response and prepulse inhibition. The beta2-agonist isoproterenol increased the startle response 
without affecting prepulse inhibition. Both the alpha1 adrenoceptor agonist phenylephrine and the 
alpha1 adrenoceptor antagonist phentolamine did not alter the startle response or prepulse 
inhibition. Noteworthy, a joint application of isoproterenol and phentolamine reduced the startle 
response compared to isoproterenol alone. Furthermore this combination decreased prepulse 
inhibition compared to saline treated rats.  
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Fig 21: PPI after accumbal injection of alpha adrenergic drugs 
Startle response 
Intraperitoneal (Carasso, Bakshi, and Geyer, 1998) or intrathecal (Astrachan and Davis, 1981) 
application of alpha1-agonist were found to increase the startle response whereas a beta2-agonist 
had no effect. This is in line with a previous study from our laboratory (Sontag, Cools, and 
Ellenbroek, 2003b submitted), where we reported no effect of the beta2- agonist clenbuterol on the 
startle after intraperitoneal injection. In the present study we found the opposite after accumbal 
application: phenylephrine had no effect on startle, whereas isoproterenol in the highest dose 
significantly increased the startle response. Thus the present study suggests that accumbal alpha1  
adrenoceptors are unlikely to contribute to the increased startle response seen after systemic 
application. It is more difficult to explain why local accumbal, but not systemic application of a beta 
agonist increased the startle response. One possibility might be that the effects of stimulation of 
accumbal beta receptors are counteracted by beta receptors in another brain structure. 
Alternatively, different beta receptors might be involved. Thus, clenbuterol (which is ineffective 
after systemic application) is a beta2 agonist, whereas isoproterenol (which is effective after local 
application) is a mixed beta1/beta2 agonist.  
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Fig 22: PPI after accumbal injection of adrenergic drugs. The combined injection of phentolamine and isoproterenol reduced the ppi. 
** p < 0.01 
Prepulse inhibition 
The main interest of this study was to investigate the effects of intra-accumbal applied 
noradrenergic drugs on prepulse inhibition in rats. As discussed in the introduction, both alpha1 
agonists and antagonists and beta2 agonists can increase the release of dopamine when applied to 
the nucleus accumbens (Tuinstra and Cools, 2000). However, even though several papers have 
shown that increasing the dopamine transmission in the nucleus accumbens reduces prepulse 
inhibition (Swerdlow, Mansbach et al., 1990), we did not find any reduction after application of a 
adrenoceptor agonist or antagonist. Interestingly, when the beta2 agonist isoproterenol was 
combined with the alpha1 antagonist phentolamine, prepulse inhibition was significantly reduced. It 
has been suggested that, in order to disrupt prepulse inhibition, the increase in dopamine release in 
the accumbens must be very high (Zhang, Pouzet et al., 2000), which would be in line with the 
current data. However, the data actually suggest that it is not just the amount of dopamine that is 
relevant, but that it might be the combined activation of two independent dopaminergic systems 
that is essential for disruption of prepulse inhibition. Thus according to the gating theory proposed 
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 by Cools and colleagues (Cools, van den Bos, Ploeger, and Ellenbroek, 1991) the accumbal 
dopamine release is controlled by two distinct systems. The stimulation of beta2-adrenoceptors 
increases the dopaminergic activity at a system that is associated with the D2-receptors, and 
inhibition of the alpha1 adrenoceptors increases the dopaminergic activity at a system which is 
associated with a dopamine receptor that differs from the classical D1 and D2 receptor. 
Furthermore, the noradrenergic activity in the nucleus accumbens is known to regulate the 
information input of the hippocampus (via the beta2 and D2 receptor system) and the basolateral 
amygdala (via the alpha1 and non D2 receptor system). According to the gating theory an increase in 
noradrenergic activity results in a closed hippocampal gate because of the activation of the beta2 
adrenoceptors and a open amygdala gate because of the activation of the alpha1-adrenoceptors. The 
opposite is found when the noradrenergic activity is decreased: the hippocampus gate is open 
because of the inhibition of the beta2-adrenoceptors and the amygdala gate is closed because of the 
inhibition of the alpha1-adrenoceptors. (for further details see (Cools, van den Bos, Ploeger, and 
Ellenbroek, 1991)).This implies that under normal circumstances either the hippocampal gate is 
closed and the amygdala gate is open or the hippocampal gate is open and the amygdala gate is 
closed.  
Based on this model, the beta2-adrenoceptor agonist isoproterenol blocked the information input 
from the hippocampus but allows the information input from the basolateral amygdala. Likewise 
the alpha1-adrenoceptor antagonist phentolamine is expected to block the information input from 
the basolateral amygdala, but allows information input from the hippocampus. Neither of these 
treatments affected prepulse inhibition. However the combined infusion of both drugs, thus 
blocking the information input from both structures significantly reduces prepulse inhibition. A 
similar finding was reported by Roosendaal and colleagues (Roozendaal and Cools, 1994). They 
showed that the neophobic response of rats was only altered when the information input of both 
structures was blocked. These data suggest that an imbalance of information input from the 
basolateral amygdala and the hippocampus are involved in prepulse inhibition. Interestingly, both 
the basolateral amygdala and the hippocampus are known to modulate prepulse inhibition. For 
example lesions of the amygdala (Decker, Curzon et al., 1995; Wan and Swerdlow, 1997) and the 
ventral subilicum, as part of the hippocampus (Swerdlow, Taaid et al., 2000) were found to reduce 
prepulse inhibition. Furthermore infusion of the glutamate agonist NMDA in the ventral 
hippocampus reduced prepulse inhibition, an effect that was blocked by the NMDA-Antagonist 
AP5 (Wan, Caine et al., 1996; Wan and Swerdlow, 1996). On the other hand Bakshi and colleagues 
reported that infusion of the NMDA-antagonist dizocilpine in the dorsal hippocampus reduced 
prepulse inhibition (Bakshi and Geyer, 1998). Furthermore, dizocilpine or picrotoxin infusion in 
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 the basolateral amygdala disrupted prepulse inhibition an effect that was blocked by the dopamine 
antagonist haloperidol (Fendt, Schwienbacher et al., 2000). In contrast to our findings the 
aforementioned authors found alterations in prepulse inhibition when either the basolateral 
amygdala or the hippocampus was manipulated. However this does not exclude that these 
manipulations induced an imbalance of information input from the basolateral amygdala and the 
hippocampus to the nucleus accumbens, reducing prepulse inhibition. 
In summary these data suggest that the noradrenergic activity in the nucleus accumbens modulates 
prepulse inhibition, most likely by increasing the dopaminergic activity. Furthermore since 
noradrenaline regulates the information input from the basolateral amygdala and the hippocampus 
to the nucleus accumbens, the presented data suggest that an imbalance in this information flow 
might contribute to disturbances in prepulse inhibition.  
Reference List 
1.  Astrachan DI, Davis M (1981) Spinal modulation of the acoustic startle response: the role of norepinephrine, 
serotonin and dopamine. Brain Res. 206: 223-228 
2.  Bakshi VP, Geyer MA (15-10-1998) Multiple limbic regions mediate the disruption of prepulse inhibition 
produced in rats by the noncompetitive NMDA antagonist dizocilpine. J.Neurosci. 18: 8394-8401 
3.  Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies [see 
comments]. Arch.Gen.Psychiatry 47: 181-188 
4.  Carasso BS, Bakshi VP, Geyer MA (1998) Disruption in prepulse inhibition after alpha-1 adrenoceptor 
stimulation in rats. Neuropharmacology 37: 401-404 
5.  Cedarbaum JM, Aghajanian GK (1978) Afferent projections to the rat locus coeruleus as determined by a 
retrograde tracing technique. J.Comp.Neurol. 178: 1-16 
6.  Cools AR, Brachten R, Heeren D, Willemen A, Ellenbroek B (1990) Search after neurobiological profile of 
individual-specific features of Wistar rats. Brain Res.Bull. 24: 49-69 
7.  Cools AR, Gingras MA (1998) Nijmegen high and low responders to novelty: a new tool in the search after the 
neurobiology of drug abuse liability. Pharmacol.Biochem.Behav. 60: 151-159 
8.  Cools AR, van den Bos R, Ploeger GE, Ellenbroek B (1991) Gating Function of Noradrenaline in the ventral 
Striatum: Its Role in Behavioral Responses to Environmental and Pharmacological Challenges. In: Willner P, 
Scheel-Kruger J. (eds) The Mesolimbic Dopamine System: From Motivation to Action. John Wiley & Sons, 
Chichester, New York, Brisbane,Toronto, Singapore, pp 141-173 
9.  Decker MW, Curzon P, Brioni JD (1995) Influence of separate and combined septal and amygdala lesions on 
memory, acoustic startle, anxiety, and locomotor activity in rats. Neurobiol.Learn.Mem. 64: 156-168 
10.  Fendt M, Schwienbacher I, Koch M (2000) Amygdaloid N-methyl-D-aspartate and gamma-aminobutyric acid(A) 
receptors regulate sensorimotor gating in a dopamine-dependent way in rats. Neuroscience 98: 55-60 
11.  Kretschmer BD, Koch M (1998) The ventral pallidum mediates disruption of prepulse inhibition of the acoustic 
startle response induced by dopamine agonists, but not by NMDA antagonists. Brain Res. 798: 204-210 
12.  Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic Coordinates. Academic, San Diego 
 73
 13.  Reijmers LG, Vanderheyden PM, Peeters BW (1995) Changes in prepulse inhibition after local administration of 
NMDA receptor ligands in the core region of the rat nucleus accumbens. Eur.J.Pharmacol. 272: 131-138 
14.  Roozendaal B, Cools AR (1994) Influence of the noradrenergic state of the nucleus accumbens in basolateral 
amygdala mediated changes in neophobia of rats. Behav.Neurosci. 108: 1107-1118 
15.  Saigusa T, Tuinstra T, Koshikawa N, Cools AR (1999) High and low responders to novelty: effects of a 
catecholamine synthesis inhibitor on novelty-induced changes in behaviour and release of accumbal dopamine. 
Neuroscience 88: 1153-1163 
16.  Sontag, T. A., Cools, A. R., and Ellenbroek, B. A. Prepulse inhibition in apomorphine susceptible (APO-SUS) 
and apomorphine unsusceptible (APO-UNSUS) rats: Effects of Depletion of Noradrenaline.  2003. (submitted) 
17.  Sontag TA, Cools AR, Ellenbroek BA (2003) Removal of short-term isolation stress differentially influences 
prepulse inhibition in APO-SUS and APO-UNSUS rats. Behav.Brain Res 141: 171-175 
18.  Sontag, T. A., Cools, A. R., and Ellenbroek, B. A. The Effect of adrenoceptor agonists on prepulse inhibition in 
apomorphine susceptible (APO-SUS) and apomorphine unsusceptible (APO-UNSUS) rats.  2003 (submitted) 
19.  Swerdlow NR, Caine SB, Geyer MA (1992) Regionally selective effects of intracerebral dopamine infusion on 
sensorimotor gating of the startle reflex in rats. Psychopharmacology Berl. 108: 189-195 
20.  Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: 
current knowledge and future challenges. Psychopharmacology (Berl) 156: 194-215 
21.  Swerdlow NR, Mansbach RS, Geyer MA, Pulvirenti L, Koob GF, Braff (1990) Amphetamine disruption of 
prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology 
Berl. 100: 413-416 
22.  Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson (1995) Impaired prepulse inhibition of 
acoustic and tactile startle response in patients with Huntington's disease. J.Neurol.Neurosurg.Psychiatry 58: 192-
200 
23.  Swerdlow NR, Taaid N, Halim N, Randolph E, Kim YK, Auerbach P (2000) Hippocampal lesions enhance 
startle gating-disruptive effects of apomorphine in rats: a parametric assessment. Neuroscience 96: 523-536 
24.  Tuinstra T, Cools AR (2000) High and low responders to novelty: effects of adrenergic agents on the regulation 
of accumbal dopamine under challenged and non-challenged conditions. Neuroscience 99: 55-64 
25.  Varty GB, Bakshi VP, Geyer MA (1999) M100907, a serotonin 5-HT2A receptor antagonist and putative 
antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. 
Neuropsychopharmacology. 20: 311-321 
26.  Wan FJ, Caine SB, Swerdlow NR (1996) The ventral subiculum modulation of prepulse inhibition is not 
mediated via dopamine D-2 or nucleus accumbens non-NMDA glutamate receptor activity. Eur.J.Pharmacol. 
314: 9-18 
27.  Wan FJ, Swerdlow NR (1993) Intra-accumbens infusion of quinpirole impairs sensorimotor gating of acoustic 
startle in rats. Psychopharmacology Berl. 113: 103-109 
28.  Wan FJ, Swerdlow NR (1996) Sensorimotor gating in rats is regulated by different dopamine-glutamate 
interactions in the nucleus accumbens core and shell subregions. Brain Res. 722: 168-176 
29.  Wan FJ, Swerdlow NR (1997) The basolateral amygdala regulates sensorimotor gating of acoustic startle in the 
rat. Neuroscience 76: 715-724 
30.  Zhang W, Pouzet B, Jongen-Relo AL, Weiner I, Feldon J (2000) Disruption of prepulse inhibition following N-
methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a 
possible model for the screening of atypical antipsychotics. Neuroreport. 10: 2533-2538 
 74
  C h a p t e r  6  
SUMMARY OF THE RESULTS 
The aim of this study was to investigate the role of stress and noradrenaline in schizophrenia and to 
further understand the neuronal mechanism involved. Among other symptoms, reductions in 
prepulse inhibition have been found in these patients. This paradigm is a very value tool for 
instigating the neurobiology of schizophrenia since this behavioural response can be measured both 
in humans and in animals. This opens the possibility to use animals in schizophrenia research. In 
our experiments we used the so-called APO-SUS and APO-UNSUS rats because APO-SUS rats 
share a large number of similarities with schizophrenic patients like impairments in their response 
to stress, as well as alterations in their noradrenergic and dopaminergic system, and, even more 
importunately, a reduction in prepulse inhibition. 
It is known that stress can worsen the symptoms of schizophrenia, for example abrupt changes in 
life increase the risk of relapse in schizophrenic patients (Jones, Babington et al., 1993). We 
therefore expected to find that stress would worsen the prepulse inhibition in APO-SUS rats 
(chapter 2). We used one day of social isolation as a stressor. In line with our expectation stressed 
APO-SUS rats displayed a decrease in prepulse inhibition and furthermore APO-UNSUS rats 
displayed an increase in prepulse inhibition. Further evidence for the effect of stress on prepulse 
inhibition in APO-SUS and APO-UNSUS rats was obtained in chapter 4. We found evidence that 
a single saline injection, known to act as a stressor, given two weeks before testing reduces the 
prepulse inhibition in APO-SUS rats and increases it in APO-UNSUS rats.  
Thus stress can elicit deficits in prepulse inhibition in APO-SUS rats, an effect that is 
similar to the finding that stress can elicit psychotic episodes in schizophrenic patients. 
Therefore these data further validate the APO-SUS rats as a good model for schizophrenia.  
One characteristic of APO-SUS and APO-UNSUS rats is that stress increases the functional 
noradrenergic activity in APO-SUS rats but decreases the functional noradrenergic activity in APO-
UNSUS rats (Cools, Brachten et al., 1990; Roozendaal and Cools, 1994). The fact that stress 
decreased prepulse inhibition in APO-SUS rats and increased prepulse inhibition in APO-UNSUS 
rats indicates that an increase in noradrenergic activity reduces prepulse inhibition. This is in line 
with the elevated levels of noradrenaline that are found in schizophrenic patients (van Kammen, 
Peters et al., 1989). Furthermore as mentioned in the Introduction these levels correlate with 
schizophrenic symptoms (van Kammen and Gelernter, 1987; Dajas, Barbeito et al., 1983). These 
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 data strongly suggest that there exists a functional relation between stress, increased noradrenaline 
levels and the worsening of schizophrenic symptoms. The situation in the stressed APO-SUS rats is 
similar since they have a high functional noradrenergic activity, induced by stress, and a reduced 
prepulse inhibition. The nature of the involved adrenergic receptors is not studied in detail. 
Therefore we investigated the effects of the beta2-adrenoceptor agonist clenbuterol and the alpha1-
adrenoceptor agonist cirazoline on prepulse inhibition in non-stressed APO-SUS and APO-
UNSUS rats (chapter 3). According to our expectation we found that the alpha1-adrenoceptor 
agonist cirazoline reduced prepulse inhibition in non-stressed APO-SUS rats, an effect that could 
be antagonised with the alpha1-adrenoceptor antagonist prazosin. Only a weak, non-significant 
effect was seen in non-stressed APO-UNSUS rats. In addition the beta2-adrenoceptor agonist 
clenbuterol had no effect on the prepulse inhibition. These findings show that the alpha1-
adrenoceptors are involved in modulating the prepulse inhibition a finding that is in line with 
previous studies (Carasso, Bakshi et al., 1998). Even more interesting, we show that only the APO-
SUS rats display reductions in prepulse inhibition after the treatment with prazosin, indicating that 
the APO-SUS rats are more sensitive to the alpha1 agonist than the APO-UNSUS rats. This is again 
in line with the idea that the APO-SUS rats are more sensitive to stress and thus are a good animal 
model for schizophrenia. To our knowledge no one has so far investigated the sensitivity of 
schizophrenic patients to noradrenergic agonists.  
Taken these two sets of data together (chapter 2 and 3), it seems highly likely that the 
disruptive effect of a mild stressor on prepulse inhibition in a valid animal model of 
schizophrenia is due to an increased activity of noradrenaline.  
At present it is not known which neuronal structures are involved in the modulation of prepulse 
inhibition by stress or noradrenaline. As mentioned in the Introduction, noradrenergic fibres from 
the locus coeruleus innervate the part of the PVN that contains terminals of CRH-releasing 
neurons that, in turn modulate the stress response of the HPA-axis. Thus the noradrenergic 
terminals from the locus coeruleus regulate the stress response. In addition the locus coeruleus 
innervates the nucleus accumbens, namely a structure known to play a role in prepulse inhibition. 
We therefore hypothesized that the locus coeruleus is also involved in modulating prepulse 
inhibition.  
In order to investigate this we blocked the noradrenergic input by selectively destroying the 
terminals of the locus coeruleus with the help of the neurotoxin DSP4. Given the inverse 
relationship between noradrenaline and prepulse inhibition, we expected an improvement in 
prepulse inhibition since the destruction of the locus coeruleus terminals reduces the noradrenergic 
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 activity. The effects of DSP4 on the prepulse inhibition in stressed and non-stressed APO-SUS and 
APO-UNSUS rats are described in chapter 4. We found that DSP4 had no effect on prepulse 
inhibition in non-stressed (non-isolated) APO-SUS rats or APO-UNSUS rats. However in line with 
the expectations, stressed DSP4-treated APO-UNSUS rats displayed an improved prepulse 
inhibition. Interestingly the stressed DSP4-treated APO-SUS rats displayed a reduced prepulse 
inhibition suggestive for an increased noradrenergic activity or an increased adrenoceptor 
sensitivity. We could indeed show that the treatment with DSP4 induced supersensitive alpha1-
adrenoceptors in APO-SUS rats, but not in APO-UNSUS rats. Although the treatment with DSP4 
reduces the noradrenergic activity, it should be noted that this treatment selectively destroys the 
locus coeruleus terminals. Therefore, other noradrenergic sources in the brain like the medullary 
group are still active. As mentioned above, stress increases the functional noradrenergic activity in 
APO-SUS rats. Thus, since the DSP4 treated APO-SUS rats have developed supersensitive alpha1-
adrenoceptors a small increase in noradrenergic activity can already reduce prepulse inhibition. It is, 
at present unclear why only APO-SUS rats developed alpha1 adrenoceptor supersensitivity. One 
possibility might be that DSP4 induced a larger reduction in noradrenaline levels in APO-SUS than 
in APO-UNSUS rats. DSP4 is taken up by the cell via the noradrenaline reuptake mechanism 
(Jonsson, Hallman et al., 1981). Since the adrenoceptor sensitivity is known to adapt to the 
noradrenergic activity, one can imagine that the same holds true for the sensitivity of the reuptake 
mechanism. Thus, rats with a high noradrenergic activity would have a high reuptake, whereas rats 
with a low noradrenergic activity would have a low reuptake. This implies that DSP4 is more toxic 
to rats that have high noradrenergic activity because more of this substance is taken up by the cell. 
As mentioned above, the injection stressed the rats and accordingly enhances the noradrenergic 
activity in APO-SUS rats, but decreases it in APO-UNSUS rats. Therefore, more DSP4 is taken up 
by APO-SUS rats resulting in more destroyed terminals and a stronger reduction in noradrenergic 
activity. To compensate this reduction the postsynaptic alpha1-adrenoceptors develop 
supersensitivity. Since the injection reduces the noradrenergic activity in APO-UNSUS, less DSP4 
is taken up and fewer terminals are destroyed. Therefore the noradrenergic activity is less reduced 
in APO-UNSUS rats and accordingly not compensated by the development of supersensitive 
alpha1-adrenoceptors receptors. However, until noradrenaline levels have been measured in APO-
SUS rats and APO-UNSUS rats, this explanation remains speculative. 
The data show that the noradrenergic terminals of the locus coeruleus are an important 
modulator of the prepulse inhibition. The role of the medullary group in this respect 
remains to be investigated 
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 Among others the locus coeruleus sends fibers to the nucleus accumbens (Speciale, Crowley et al., 
1978), a structure that is known to modulate prepulse inhibition. For example increasing the 
dopaminergic activity in this nucleus has been found to reduce prepulse inhibition (Swerdlow, 
Geyer et al., 2001). This is in line with the fact that amphetamine and other dopamine releasing 
drugs can induce a state resembling paranoid schizophrenia in normal individuals (Connell, 1958) 
and reduce prepulse inhibition in both humans (Hutchison and Swift, 1999) and rats (Mansbach, 
Geyer et al., 1988). Within the nucleus accumbens noradrenaline is known to control dopamine 
release (Tuinstra and Cools, 2000). This leads to the hypothesis that noradrenaline modulates the 
prepulse inhibition by altering the dopamine activity in the nucleus accumbens. In order to test this 
hypothesis we applied different noradrenergic agents in the nucleus accumbens and tested the 
effects on prepulse inhibition in rats. 
This experiment was based on the microdialysis study by Tuinstra and colleagues (Tuinstra and 
Cools, 2000). The authors showed that both the alpha1-adrenoceptor agonist phenylephrine and the 
beta2-agonist isoproterenol increase the accumbal dopamine release. Notably also the alpha1-
adrenoceptor antagonist phentolamine was found to increase accumbal dopamine. The authors 
concluded that the agonist acts at the presynaptic site thereby inhibiting the release of noradrenaline 
from its terminals and subsequently disinhibits the release of dopamine. The antagonist on the 
other hand acts directly by inhibiting the postsynaptic receptors on the corresponding dopamine 
terminals facilitating the release of dopamine. Based on these facts we expected to find a reduction 
in prepulse inhibition in rats after the application of phentolamine, isoproterenol and phenylephrine 
(chapter 5).  
Intra-accumbal injection of neither the alpha1-adrenoceptor agonist phenylephrine nor the beta2-
adrenoceptor agonist isoproterenol altered prepulse inhibition in rats. Also the alpha1-adrenoceptor 
antagonist phentolamine was ineffective in this respect. Interestingly, when given together, 
isoproterenol and phentolamine significantly reduced prepulse inhibition. This suggests a 
cumulative effect of these two drugs on dopamine. As shown by Zhang and colleagues, the 
increase in accumbal dopamine must be up to 100% to disrupt prepulse inhibition (Zhang, Pouzet 
et al., 2000). More importantly, it should be noted that there are two distinct noradrenergic-
dopaminergic systems in the nucleus accumbens. According to the gating theory by Cools and 
colleagues (Cools, van den Bos et al., 1991) beta2-adrenoceptor agonists increase the dopaminergic 
activity at the level of the D2-receptors, whereas alpha1-adrenoceptor antagonists  increase the 
dopaminergic activity at the level of a subtype of dopamine receptors that differs from the classical 
D1 and D2 type of receptors. Since neither isoproterenol nor phentolamine alone altered prepulse 
inhibition, these data strongly suggests that activation of both types of dopamine receptors is 
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 required for a reduction in prepulse inhibition. Furthermore, according to the gating theory the 
increase in accumbal dopamine is associated with regulation of the information input to the nucleus 
accumbens. Increasing dopaminergic activity at the level of the D2 receptors, by activating the 
accumbal beta2-adrenoceptors, blocks the information input from the hippocampus. On the other 
hand increasing the dopaminergic activity at the level of the non-classical D1/D2 subtype of 
dopamine receptors, by inhibiting the accumbal alpha1-adrenoceptors, blocks the information input 
of the amygdala. Since it was found that prepulse inhibition was only reduced when isoproterenol 
and phentolamine were given together, these data strongly suggests that reductions in prepulse 
inhibition can only be observed when the information flow from both nuclei is blocked. This is in 
line with previous data on neophobia, in which a disturbance was only observed when both the 
hippocampal and the amygdale gate were closed (Roozendaal and Cools, 1994). This finding 
suggests that information input from both the amygdala and the hippocampus is necessary for a 
correct prepulse inhibition. It was already found that hippocampus and amygdala modulate 
prepulse inhibition. For example infusion of the NMDA antagonist dizocilipine in the basolateral 
amygdala reduces prepulse inhibition (Fendt, Schwienbacher et al., 2000). In addition infusion of 
the of the glutamate agonist NMDA in the ventral hippocampus reduces prepulse inhibition (Wan, 
Caine et al., 1996). Lesions of the entorhinal cortex (which constitutes the principal output 
connection of the hippocampus to the nucleus accumbens) reduces prepulse inhibition (Goto, Ueki 
et al., 2002). Interestingly, this effect is reversed by systemic application of the D2 dopamine 
antagonist haloperidol. Although it is not clear whether this reversal occurs at the level of the 
nucleus accumbens, it is in line with the gating theory, which states that the hippocampal gate is 
controlled by D2 receptors in the nucleus accumbens. 
Anyhow, these data show that accumbal noradrenaline modulates prepulse inhibition. The 
fact that noradrenaline increases accumbal dopamine together with the fact that an 
increased dopamine activity in the nucleus accumbens reduces prepulse inhibition 
suggests that noradrenaline reduced prepulse inhibition by increasing accumbal 
dopamine. Furthermore these data indicate that the information input from both the 
amygdala and the hippocampus is required for a correct prepulse inhibition.  
In summary the data presented in this thesis demonstrate that stress modulates prepulse inhibition. 
Furthermore we were able to show that this effect is based on an increase in noradrenergic activity, 
most likely by activating the locus coeruleus. Finally we found evidence that noradrenaline 
modulates prepulse inhibition in the nucleus accumbens, presumably by modulating accumbal 
dopamine and thus regulating the information input from the amygdala and the hippocampus to 
the nucleus accumbens.  
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 In the following chapter we discuss the consequences of these findings for the modulation of the 
prepulse inhibition and the treatment for schizophrenia.  
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  C h a p t e r  7  
CONCLUDING REMARKS 
Neuronal regulation of prepulse inhibition: Koch’s model revised. 
 
As discussed in the Introduction, there is extensive knowledge about the neuronal structures that 
are mediating and regulating prepulse inhibition (see Fig 1, Chapter 1). Nevertheless, this study has 
provided the original evidence that a hitherto unstudied brain structure in this respect has to be 
added, namely the locus coeruleus. In this thesis hard evidence is presented that the locus coeruleus 
as well as its axons that terminate in the nucleus accumbens are crucial for the presence of a normal 
prepulse inhibition. Apart from this, the present study shows that beta-adrenoceptors in the 
nucleus accumbens that are known to belong to the noradrenergic fibres that arise in the locus 
coeruleus (see: Cools, van den Bos, Ploeger, and Ellenbroek, 1991) are important, though 
stimulation or inhibition of these receptors alone is insufficient for altering the prepulse inhibition. 
In addition, this study shows that alpha-adrenoceptors in the nucleus accumbens are also important 
for the regulation of prepulse inhibition, though, like the beta-adrenoceptors in this nucleus, just 
stimulation or inhibition of these receptors is insufficient for altering prepulse inhibition. 
Previously, it has been postulated that the alpha-adrenoceptors in the nucleus accumbens belong to 
noradrenergic fibres that arise in the medullary cell group, the so-called A2-A5 group (see: Cools, 
van den Bos, Ploeger, and Ellenbroek, 1991). In view of this, we suggest that also this medullary 
group is a neuronal structure that plays a role in prepulse inhibition. In other words, both the locus 
coeruleus and the medullary cell groups should be added to the brain nuclei that regulate or mediate 
prepulse inhibition. Analysis of Figure 1 in chapter 1 reveals that noradrenaline is not at all included 
as a neurotransmitter that plays a crucial role in prepulse inhibition. As extensively discussed above, 
this thesis provides hard evidence that central noradrenaline is crucial for the regulation and 
mediation of prepulse inhibition. Interestingly, the accumbal adrenoceptors are known to control 
accumbal dopamine, a neurotransmitter that, in turn, is known to control the glutaminergic input 
from the basolateral amygdala and the ventral hippocampus (for details see: Cools, van den Bos, 
Ploeger, and Ellenbroek, 1991). Just briefly, activating the accumbal beta2 adrenoceptors increases 
the activity at the level of the accumbal D2 receptors thereby blocking the glutaminergic input from 
the ventral hippocampus to the nucleus accumbens. On the other hand, inhibition of the accumbal 
alpha1-adrenoceptors increases the activity at the level of a non D2-subtype of dopaminergic 
receptor (Cools, van den Bos, Ploeger, and Ellenbroek, 1991) thereby blocking the glutaminergic  
input from the basolateral amygdala. The data of this thesis clearly shows that the prepulse 
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 inhibition is only reduced if an inhibition of accumbal alpha1-adrenoceptors is combined with a 
stimulation of beta2-adrenoceptors. According to the earlier described and above-mentioned gating 
theory, this implies that a combined inhibition of the amygdala and the hippocampal input of the 
nucleus accumbens results in an impaired prepulse inhibition. Indeed, it is already known that 
manipulations with the amygdala or the hippocampus alter prepulse inhibition. The notion that 
there exists both an accumbal dopamine D2-dependent and an accumbal dopamine D2-independent 
mechanism that is involved in prepulse inhibition, is fully in line with the findings of Wan and 
colleagues (Wan and Swerdlow, 1996): they have found that the dopamine D2 antagonist 
haloperidol  antagonizes the AMPA-induced impairment of prepulse inhibition, when this drug is 
administered into the core of the nucleus accumbens, whereas it does not antagonize the AMPA-
induced impairment of the prepulse inhibition, when AMPA is infused into the shell of the nucleus 
accumbens. These data open the perspective that both the beta2-adrenoceptors and the dopamine 
D2 receptors that regulate prepulse inhibition in the nucleus accumbens, are primarily localized in 
the core, and that both the alpha1-adrenoceptors and the dopamine non-D2 receptors that regulate 
prepulse inhibition in the nucleus accumbens, are primarily localized in the shell of the nucleus 
accumbens. Because no additional evidence in this respect is available, future studies are required to 
(in) validate these hypotheses. As a final remark in this context, there is evidence that the nucleus 
accumbens contains at least two distinct output pathways of the nucleus accumbens by which 
prepulse inhibition is transmitted (Kretschmer and Koch, 1998). This knowledge was already 
included in Koch’s diagram depicting the brain nuclei involved in prepulse inhibition, namely one 
accumbal output pathway that terminates in the ventral pallidum and one accumbal output pathway 
that terminates in the pedunculopontine tegmental nucleus. Because it has been reported that the 
impairment of prepulse inhibition following accumbal administration of the dopamine D2/ D1 
agonist apomorphine is fully inhibited by a lesion in the ventral pallidum, it becomes attractive to 
postulate that dopamine D2 controlled hippocampal input of the nucleus accumbens impinges 
upon neurons that innervate the ventral pallidum. On the other hand, the prepulse inhibition 
impairment induced by accumbal administration of a glutaminergic antagonist of NMDA-receptors 
is not inhibited by a lesion of the ventral pallidum. In view of this, one might speculate that the 
basolateral amygdala input of the nucleus accumbens impinges upon neurons that bypasses the 
ventral pallidum and, possibly, terminate on the pedunculopontine tegmental nucleus. In view of all 
these data, we decided to revise the original diagram of Koch (Koch, 1999). The results are 
depicted in Fig 23. The putative input-output connections between the ventral subiculum of the 
hippocampus, core and ventral pallidum on one hand and those between the basolateral part of the 
amygdala, the shell and the pedunculopontine nucleus on the other hand are incorporated in Fig 24. 
It is evident that this model gives rise to a number of hypotheses that can be tested.  
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Fig 23: noradrenaline modulates prepulse inhibition. BLA: basolateral amygdala; VS: ventral subilicum ; Da: Dopamine; Glu: 
glutamate 
First, our model states that both the hippocampal and the amygdala input of the nucleus 
accumbens have to be inhibited in order to impair prepulse inhibition. Therefore it becomes 
worthwhile to study whether or not simultaneous stimulation of the involved glutamate receptors 
in both the ventral subiculum of the hippocampus and the basolateral part of the amygdala is 
required to disturb prepulse inhibition. Second, our model states that stimulation of both types of 
dopamine receptors in the nucleus accumbens is required for producing an impaired prepulse 
inhibition. Accordingly, the question arises to what extent simultaneous stimulation of these 
receptors is effective or not in this respect. Furthermore, since these dopamine receptors are 
associated with different noradrenergic receptors it is important to validate to what extent these 
effects are dependent on these different noradrenergic receptors. Third, our model states that both 
the nucleus accumbens output towards the ventral pallidum and the nucleus accumbens output to 
the pedeunculopontine tegmental nucleus have to be blocked in order to disrupt prepulse 
inhibition. Accordingly, the question arises to what extent a simultaneous blockade of the GABA-
ergic receptors in the ventral pallidum and peduculopontine tegmental nucleus is required in order 
to worsen prepulse inhibition. It is clear that our model provides a firm foundation for extending 
 84
 our present-day knowledge about the involvement of distinct brain structures in the mediation and 
regulation of prepulse inhibition. Future studies are necessary to collect hard data in this respect. 
 
Fig 24: Putative neuronal connection in the nucleus accumbens, modulating prepulse inhibition:BLA: basolateral amygdala; VLS: 
ventral subilicum ; Da: Dopamine; Glu: glutamate 
Implications for schizophrenia  
As discussed in the Introduction, stress is known to increase the risk of relapse in schizophrenic 
patients: it can actually elicit psychotic episodes in schizophrenic patients. One of the symptoms 
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 seen in schizophrenic patients is a reduced prepulse inhibition (Braff, Stone et al., 1978). As 
elaborated in the Introduction, this can be mimicked in animals by administering amphetamine 
(Mansbach, Geyer et al., 1988), a treatment known to elicit reduced prepulse inhibition in normal 
humans (Hutchison and Swift, 1999). Previously, it has been shown that the APO-SUS rat is a valid 
animal of certain aspects of schizophrenia. Among others these rats show an impaired prepulse 
inhibition (Ellenbroek, Geyer et al., 1995). The present study presents hard evidence that it is stress 
that triggers this phenomenon. The data presented in this thesis may provide an adequate 
explanation for the clinical finding that stress influences the display of symptoms in patients with 
schizophrenia (Koenigsberg and Handley, 1986). It is known that stress among others increases the 
central noradrenergic activity (Cullinan, Herman et al., 1995) and we were able to demonstrate that 
an increased noradrenergic activity gives rise to the display of an impaired prepulse impulse 
inhibition.  
In other words, stress can enhance the central noradrenergic activity that, in turn, triggers a 
schizophrenic symptom like a reduction of the prepulse inhibition in patients. This may explain 
why families marked by a so-called high EE, but not low EE, can have such a negative effect upon 
the relapse of schizophrenic patients in such families (Koenigsberg and Handley, 1986). The 
present study also shows that the ability of stress to elicit an impaired prepulse inhibition is limited 
to our schizophrenia-prone rats: stress reduced prepulse inhibition only in APO-SUS rats, but not 
in APO-UNSUS rats, the controls of APO-SUS rats. This suggests that especially individuals with a 
predisposition for schizophrenia are sensitive to the effect of stress upon prepulse inhibition. As 
discussed in the Introduction, increased levels of noradrenaline have been found in the brain of 
schizophrenic patients (van Kammen, Peters et al., 1989). Because the present study has provided 
hard evidence that an abnormally high activity of central noradrenaline results in a reduced prepulse 
inhibition, our data strongly suggest that the enhanced levels of central noradrenaline in the brain of 
patients with schizophrenia gives rise to the impaired prepulse inhibition in these patients.  
In this context it is important to note that the amount of central noradrenaline correlates not just 
with a single schizophrenic symptom, but with a whole set of positive and negative symptoms (van 
Kammen and Gelernter, 1987). This might imply that central noradrenaline plays not only a role in 
the impaired prepulse inhibition, but also in other schizophrenic symptoms. All these 
considerations together indicate that noradrenaline is much more important than hitherto thought: 
it is concluded that central noradrenaline needs to play an important role in the etiology of 
schizophrenia.  
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 The present findings open new perspectives for the treatment of schizophrenia. First of all, our 
data indicate that it is stress that can have a negative effect upon the relapse of symptoms in 
patients with schizophrenia. This implies that both the patient with schizophrenia and the people 
dealing with the patient have to take into account that exposure to stressors should be prevented as 
much as possible. On the basis of these considerations we advise to create a stress-free 
environment for the patients. For example, it should be advised that the patient tries to maintain a 
stable day/night rhythm. Apart from this, people dealing with the patients should be advised to 
take care of the notion that stress can really worsen the symptoms of the patient. 
Second, our data strongly indicate that the therapeutic efficacy of alpha1-adrenergic antagonists 
should be investigated. In this context it is important to note that there is already evidence that 
agents with a strong noradrenergic antagonistic component such as clozapine have already proven 
to be effective  in this respect (Kumari, Soni et al., 1999; Lee, Jayathilake et al., 1999). In sum, it is 
concluded that there is an urgent need for investigating in more detail the role of central 
noradrenaline in the etiology and therapy of schizophrenia. 
Third, as already mentioned, impaired prepulse inhibition is not limited to schizophrenia: it also 
occurs in other neuropsychiatric diseases  such as obsessive compulsive disorder (Braff, Geyer et 
al., 2001), Huntington’s disease (Swerdlow, Paulsen et al., 1995), attention deficit disorder, 
Tourette’s  syndrome (Castellanos, Fine et al., 1996) and posttraumatic stress disorder (Grillon, 
Morgan et al., 1996). Although not only noradrenaline, but also other neurotransmitters can 
contribute to an impaired prepulse inhibition, like dopamine and glutamate and 5HT (Geyer, 
Krebs-Thomson et al., 2001), it becomes interesting to investigate whether or not abnormal 
noradrenaline activity and/or metabolism also contributes to the disturbed prepulse inhibition in 
these diseases. This appears to held true for patients with Tourette’s syndrome, obsessive 
compulsive disorder (Leckman, Goodman et al., 1995), posttraumatic stress disorder (Geracioti, 
Baker et al., 2001) for, abnormal noradrenaline levels have been found in the brain of all these 
patients. To what extent noradrenaline plays also a role in the other symptoms of these diseases 
remains to be investigated in future studies. Anyhow, the role of noradrenaline in the etiology of 
these diseases needs far more attention that is has got in the past. 
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  C h a p t e r  8  
NEDERLANDSE SAMENVATTING 
Het doel van deze studie was de rol van stress en noradrenaline bij schizofrenie te bestuderen en 
om het onderliggende neuronale mechanisme beter te begrijpen. Buiten andere symptomen is de 
reductie van prepuls inhibitie gevonden in patiënten. Het paradigma is een bijzonder waardevol 
hulpmiddel om de neurobiologie van schizofrenie te bestuderen, omdat de gedragsmatige respons 
in zowel dieren als mensen kan worden bestudeerd. Dit biedt de mogelijkheid om dieren te 
gebruiken in het schizofrenieonderzoek. In onze experimenten gebruiken we de zogenaamde APO-
SUS en APO-UNSUS ratten, omdat APO-SUS ratten een groot aantal overeenkomsten hebben 
met schizofrene patiënten, zoals een minder goede reactie op stress en veranderingen in het 
noradrenerge en dopaminerge systeem en, nog belangrijker, een reductie van de prepuls inhibitie.  
 
Het is bekend dat stress de symptomen van schizofrenie kan verergeren. Abrupte veranderingen in 
het leven kunnen bijvoorbeeld het risico op een terugval van schizofrene patiënten vergroten 
(Jones, Babington et al., 1993). We verwachtten daarom te vinden dat stress de prepuls inhibitie zou 
verslechteren in APO-SUS ratten (hoofdstuk 2). We hebben slechts isolatie van één enkele dag 
gebruikt als een stressor. In overeenkomst met onze verwachtingen vertoonden APO-SUS ratten 
een verslechterde prepuls inhibitie en bovendien vertoonden APO-UNSUS ratten een verhoging in 
prepuls inhibitie. Meer bewijs voor het effect van stress op prepuls inhibitie in APO-SUS en APO-
UNSUS ratten is in hoofdstuk 4 verkregen. We hebben bewijs gevonden dat een enkele injectie 
van fysiologisch zout twee weken voor het testen, waarvan bekend is dat het als een stressor werkt, 
een verlaging van prepuls inhibitie veroorzaak in APO-SUS ratten en een verhoging in APO-
UNSUS ratten. 
Dus stress kan een verslechtering van de prepuls inhibitie bij APO-SUS ratten 
teweegbrengen, een effect dat vergelijkbaar is met het feit dat stress psychotische episodes 
kan teweegbrengen bij schizofrene patiënten. Daarom dragen deze data bij aan het verder 
valideren van APO-SUS ratten als een goed model voor schizofrenie.  
Een eigenschap van APO-SUS en APO-UNSUS ratten is dat stress de functionele noradrenerge 
activiteit verhoogt in APO-SUS ratten, maar verlaagt in APO-UNSUS ratten (Cools, Brachten et 
al., 1990; Roozendaar en Cools, 1994). Het feit dat stress de prepuls inhibitie verlaagde in APO-
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 SUS ratten en verhoogde in APO-UNSUS ratten geeft een indicatie dat een verhoging in de 
noradrenerge activiteit de prepuls inhibitie verlaagt. Dit is in overeenstemming met verhoogde 
noradrenaline spiegels die gevonden zijn in schizofrene patiënten (Van Kammen, Peters et al., 
1989). Verder, zoals genoemd in de Introductie, correleren deze spiegels met schizofrene 
symptomen (Van Kammen en Gelernter, 1987, Dajas, Barbeito et al., 1993). Deze data suggereren 
sterk dat er een functionele relatie bestaat tussen stress, noradrenaline spiegels en het verergeren 
van schizofrene symptomen. De situatie van de gestresste APO-SUS ratten is vergelijkbaar, omdat 
ze een hogere, door stress geïnduceerde, functionele noradrenerge activiteit hebben en een 
verlaagde prepuls inhibitie. De aard van de betrokken receptoren is niet in detail bestudeerd. 
Daarom hebben we de effecten van de beta2-adrenoceptor agonist clenbuterol en de alfa1-
adrenoceptor agonist cirazoline op de prepuls inhibitie bestudeerd in niet gestresste APO-SUS en 
APO-UNSUS ratten (hoofdstuk 3). In overeenstemming met onze verwachting hebben we 
gevonden dat de alfa1-adrenoceptor agonist cirazoline de prepuls inhibitie verlaagde in niet 
gestresste APO-SUS ratten, een effect dat geantagoneerd kon worden met de alfa1-adrenoceptor 
antagonist prazosine. Slechts een zwak, niet significant effect werd gezien in APO-UNSUS ratten. 
Bovendien had de beta2-adrenoceptor agonist clenbuterol geen effect op de prepuls inhibitie. Deze 
bevindingen laten zien dat alfa1-adrenoceptors betrokken zijn bij de modulatie van de prepuls 
inhibitie, een bevinding die overeen komt met voorgaande studies (Carasso, Bakshi et al., 1998). 
Nog interessanter is dat we laten zien dat alleen de APO-SUS ratten een reductie van de prepuls 
inhibitie vertonen na behandeling met prazosine en dit geeft aan dat APO-SUS ratten gevoeliger 
zijn voor de alfa1-agonist dan APO-UNSUS ratten. Dit is ook weer in overeenkomst met het idee 
dat APO-SUS ratten veel gevoeliger zijn voor stress en dus een goed diermodel voor schizofrenie 
zijn. Voor zover onze kennis strekt, heeft tot nu toe niemand de gevoeligheid van schizofrene 
patiënten voor noradrenerge agonisten onderzocht.  
Deze twee sets van data bij elkaar genomen (hoofdstukken 2 en 3), lijkt het zeer voor de 
hand liggend dat de verstorende effecten van een milde stressor op de prepuls inhibitie in 
een valide diermodel voor schizofrenie toe te schrijven zijn aan een verhoogde 
noradrenerge activiteit. 
Op dit moment is het niet bekend welke neuronale structuren betrokken zijn bij de modulatie van 
prepuls inhibitie door stress of noradrenaline. Zoals genoemd in de Introductie innerveren de 
noradrenerge vezels uit de locus coeruleus het gedeelte van de PVN dat terminals bevat van CRH-
afgevende neuronen, die, op hun beurt, de stress repons van de HPA-as beïnvloeden. Dus 
reguleren de nordrenerge terminals van de locus coeruleus de stress repons. Bovendien innerveert 
de locus coeruleus de nucleus accumbens, een structuur die betrokken is bij de regulatie van prepuls 
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 inhibitie. Om die reden hypothetiseren wij dat de locus coeruleus ook betrokken is bij de regulatie 
van prepuls inhibitie.  
Om deze hypothese the onderzoeken, hebben we de noradrenerge input geblokkeerd door selectief 
de terminals van de locus coeruleus te vernietigen door toediening van het neurotoxine DSP4. 
Wegens de omgekeerd evenredige relatie tussen noradrenaline en prepuls inhibitie, verwachtten we 
een verbetering in de prepulse inhibitie, omdat de vernietiging van de locus coeruleus terminals de 
noradrenerge activiteit verlaagt. De effecten van DSP4 op prepuls inhibitie in gestresste en niet 
gestresste APO-SUS en APO-UNSUS ratten zijn beschreven in hoofdstuk 4. We hebben 
gevonden dat DSP4 geen effect had op prepuls inhibitie in niet gestresste (niet geïsoleerde) APO-
SUS ratten of APO-UNSUS ratten. Echter, in overeenstemming met de verwachtingen, gestresste 
DSP4-behandelde APO-UNSUS ratten vertoonden een verbeterde prepuls inhibitie. Interessant is 
dat de gestresste DSP4-behandelde APO-SUS ratten een verlaging van de prepuls inhibitie 
vertoonden, wat een hoge noradrenerge activiteit of een verhoogde adrenoceptor gevoeligheid 
suggereert. We hebben inderdaad aangetoond dat de behandeling met DSP4 supersensitisatie van 
de alfa1-adrenoceptors in APO-SUS ratten veroorzaakt, maar niet in APO-UNSUS ratten. Hoewel 
de behandeling met DSP4 de noradrenerge activiteit reduceert, moet het opgemerkt worden dat 
deze behandeling de terminals van de locus coeruleus selectief vernietigt. De andere noradrenerge 
systemen in de hersenen, zoals de medullaire groep, zijn dus nog steeds actief. Zoals eerder 
genoemd, verhoogt stress de functionele noradrenerge activiteit in APO-SUS ratten. Dus, omdat de 
DSP4 behandelde APO-SUS ratten supersensitieve alfa1-adrenoceptors hebben, kan een kleine 
verhoging in noradrenerge activiteit al voor een verlaging van de prepuls inhibitie zorgen. Op dit 
moment is het onduidelijk waarom alleen APO-SUS ratten supersensitieve alfa1-receptoren hebben 
ontwikkeld. Een mogelijke verklaring kan zijn dat DSP4 een grotere reductie in noradrenaline 
spiegels veroorzaakt in APO-SUS dan in APO-UNSUS ratten. DSP4 wordt in wordt in de cel 
opgenomen via het noradrenaline heropname mechanisme (Jonsson, Hallman et al., 1981). Omdat 
het bekend is dat adrenoceptor gevoeligheid zich aanpast aan de noradrenerge activiteit, zou men 
zich kunnen voorstellen dat hetzelfde geldt voor het heropname mechanisme. Dus, ratten met een 
hoge noradrenerge activiteit zouden een hoge heropname hebben, terwijl ratten met een lage 
noradrenerge activiteit een lage heropname zouden hebben. Dit impliceert dat DSP4 meer toxisch 
is bij ratten met een hoge noradrenerge activiteit, omdat meer van deze stof opgenomen wordt in 
de cel. Zoals eerder genoemd, de injectie heeft de ratten gestresst en verhoogt daarom de 
noradrenerge activiteit in APO-SUS ratten, maar verlaagt het in APO-UNSUS ratten. Meer DSP4 
wordt dus opgenomen in APO-SUS ratten en dit resulteert in meer vernietigde terminals en een 
grotere reductie in noradrenerge activiteit. Om deze reductie te compenseren ontwikkelen de 
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 postsynaptische alfa1-adrenoceptors supersensitiviteit. Omdat de injectie de noradrenerge activiteit 
in APO-UNSUS ratten reduceert, wordt er minder DSP4 opgenomen en worden er minder 
terminals vernietigd. Daarom is de noradrenerge activiteit minder gereduceerd in APO-UNSUS 
ratten en dus vindt er geen compensatie plaats door het ontwikkelen van supersensitieve alfa1-
adrenoceptors. Echter, todat noradrenaline spiegels gemeten zijn in APO-SUS en APO-UNSUS 
ratten blijft deze verklaring speculatief. 
De data laten zien dat de noradrenerge terminals van de locus coeruleus een belangrijke 
modulator zijn van de prepuls inhibitie. De rol van de medullaire groep moet hierin nog 
worden onderzocht. 
De locus coeruleus, onder andere, projecteert vezels naar de nucleus accumbens (Speciale, Crowley 
et al., 1978), een structuur die bekend is betrokken te zijn bij de modulatie van de prepuls inhibitie. 
Het is gevonden dat de prepuls inhibitie verlaagd kan worden door bijvoorbeeld de dopaminerge 
activiteit in deze nucleus te verhogen (Swerdlow, Geyer et al., 2001). Dit is in overeenstemming met 
het feit dat amfetamine en andere drugs die de afgifte van dopamine stimuleren een toestand 
kunnen veroorzaken in normale individuen die lijkt op paranoïde schizofrenie (Connell, 1958) en 
een reductie in prepuls inhibitie in zowel mensen (Hutchison en Swift, 1999) als ratten (Mansbach, 
Geyer et al., 1998) kunnen veroorzaken. Binnen de nucleus accumbens is het bekend dat 
noradrenaline de afgifte van dopamine stuurt (Tuinstra en Cools, 2000). Dit leidt tot de hypothese 
dat noradrenaline de prepuls inhibitie moduleert door de dopaminerge activiteit in de nucleus 
accumbens te veranderen. Om deze hypothese te testen hebben we verschillende noradrenerge 
farmaca in de nucleus accumbens toegediend en het effect hiervan op de prepuls inhibitie in ratten 
getest. 
Dit experiment werd gebaseerd op de microdialyse studie van Tuinstra en collega’s (Tuinstra en 
Cools, 2000). De auteurs laten zien dat zowel de alfa1-adrenoceptor agonist phenylephrine als de 
beta2-adrenoceptor agonist isoproterenol de dopamine afgifte in de nucleus accumbens verhogen. 
Ook de alfa1-adrenoceptor antagonist phentolamine verhoogde de afgifte van dopamine. De 
auteurs hebben geconcludeerd dat de agonist presynaptisch werkt en de afgifte van noradrenaline in 
de terminals blokkeert en vervolgens de inhibitie van de dopamine afgifte opheft. De antagonist, 
daarentegen, werkt door direct de postsynaptische receptoren op de dopaminerge terminals te 
blokkeren en daarmede de dopamine afgifte te stimuleren. Op deze feiten baseren wij onze 
verwachting om een reductie van de prepuls inhibitie te vinden in ratten na de toediening van 
phentolamine, isoproterenol en phenylephrine (hoofdstuk 5).  
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 Injecties in de nucleus accumbens van noch de alfa1-adrenoceptor agonist phenylephrine, noch de 
beta2-adrenoceptor agonist proterenol veranderden de prepuls inhibitie in ratten. De alfa1-
adrenoceptor antagonist phentolamine was ook ineffectief. Wanneer samen gegeven, echter, 
reduceerden isoproterenol en phentolamine de prepuls inhibitie significant. Dit suggereert een 
cumulatief effect van deze twee drugs op dopamine. Zoals aangetoond door Zhang en collega’s 
moet de verhoging van dopamine minstens 100% zijn om de prepuls inhibitie te verstoren (Zhang, 
Pouzet et al., 2000). Nog belangrijker is om te realiseren dat er twee te onderscheiden 
noradrenerge-dopaminerge systemen in de nucleus accumbens aanwezig zijn. Volgens de gating 
theorie van Cools en collega’s (Cools, Van den Bos et al., 1991) verhogen beta2-adrenoceptor 
agonisten de dopaminerge activiteit op het niveau van de D2-receptoren, terwijl alfa1-adrenoceptor 
antagonisten de dopaminerge activiteit verhogen op het niveau van een subtype dopamine 
receptoren, dat verschilt van het klassieke D1 en D2 type van receptoren. Omdat noch 
isoproterenol, noch phentolamine alleen de prepuls inhibitie veranderden, suggereren deze data 
sterk dat activering van beide typen dopamine receptoren nodig is om een reductie in prepuls 
inhibitie te veroorzaken. Verder is, volgens de gating theorie, een verhoging van dopamine in de 
nucleus accumbens geassocieerd met de regulatie van informatie input naar de nucleus accumbens. 
De verhoging van de dopaminerge activiteit op het niveau van de D2-receptoren, door activering 
van beta2-adrenoceptors in de nucleus accumbens, blokkeert de informatie input van de 
hippocampus. De verhoging van de dopaminerge activiteit op het niveau van het niet-klassieke 
D1/D2 receptor subtype, aan de andere kant, blokkeert de informatie input van de amygdala. 
Omdat het gevonden is dat de prepuls inhibitie alleen gereduceerd werd wanneer isoproterenol en 
phentolamine samen toegediend werden, suggereren deze data sterk dat de reductie prepuls 
inhibitie slechts optreedt wanneer de informatiestroom vanuit beide kernen geblokkeerd is. Dit is in 
overeenstemming met data over neofobie, waarbij slechts een verstoring werd gevonden wanneer 
zowel de hippocampus als de amygdala gate gesloten waren (Roozendaal en Cools, 1994). Deze 
bevinding suggereert dat de informatie input uit zowel de hippocampus als de amygdala nodig zijn 
voor een correcte prepuls inhibitie. Het was al gevonden dat de hippocampus en de amygdala de 
prepuls inhibitie moduleren. Bijvoorbeeld, de infusie van de NMDA antagonist dizocilipine in de 
basolaterale amygdala reduceert de prepuls inhibitie (Fendt, Schwienbacher et al., 2000). Bovendien 
reduceert de infusie van de glutamaat agonist NMDA in de ventrale hippocampus de prepuls 
inhibitie (Wan, Caine et al., 1996). Lesies van de entorhinale cortex (welke de primaire output 
connectie vormt van de hippocampus naar de nucleus accumbens) reduceert de prepuls inhibitie 
(Goto, Ueki et al., 2002). Dit effect kan opgeheven worden door systemische toediening van de D2 
antagonist haloperidol. Hoewel het niet duidelijk is of deze opheffing plaats vindt op het niveau van 
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 de nucleus accumbens, is het toch in overeenstemming met de gating theorie, welke aangeeft dat de 
hippocampus gate gecontroleerd wordt door D2 receptoren in de nucleus accumbens.  
Hoe dan ook, deze data laten zien dat noradrenaline in de nucleus accumbens de prepuls 
inhibitie moduleren. Het feit dat noradrenaline de afgifte van dopamine in de nucleus 
accumbens verhoogt, samen met het feit dat een verhoogde dopaminerge activiteit in de 
nucleus accumbens de prepuls inhibitie reduceert, suggereert dat noradrenaline de prepuls 
inhibitie reduceert door de verhoging van dopamine. Bovendien duiden deze data erop dat 
de informatie input van zowel de hippocampus als de amygdala nodig zijn voor een 
correcte prepuls inhibitie. 
Samenvattend, de gepresenteerde data in dit proefschrift laten zien dat stress de prepuls inhibitie 
moduleert. Bovendien hebben we laten zien dat dit effect gebaseerd is op de verhoging in 
noradrenerge activiteit, meest waarschijnlijk door activatie van de locus coeruleus. Ten slotte 
hebben we bewijs gevonden dat noradrenaline de prepuls inhibitie moduleert in de nucleus 
accumbens, waarschijnlijk door dopamine in de nucleus accumbens te beïnvloeden, en 
dientengevolge de informatie input van de amydala en de hippocampus naar de accumbens te 
reguleren. 
In hoofdstuk 7 bediscussiëren we de consequenties van deze bevindingen voor de modulatie van 
prepuls inhibitie en de behandeling van schizofrenie.  
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